CA2562829A1 - Oxygenated dibenzo-alpha-pyrone chromoproteins - Google Patents
Oxygenated dibenzo-alpha-pyrone chromoproteins Download PDFInfo
- Publication number
- CA2562829A1 CA2562829A1 CA002562829A CA2562829A CA2562829A1 CA 2562829 A1 CA2562829 A1 CA 2562829A1 CA 002562829 A CA002562829 A CA 002562829A CA 2562829 A CA2562829 A CA 2562829A CA 2562829 A1 CA2562829 A1 CA 2562829A1
- Authority
- CA
- Canada
- Prior art keywords
- dcps
- composition according
- composition
- alpha
- shilajit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 claims abstract description 144
- 238000009472 formulation Methods 0.000 claims abstract description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 19
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 17
- -1 fatty acyl esters Chemical class 0.000 claims abstract description 17
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000016709 nutrition Nutrition 0.000 claims abstract description 15
- 235000014653 Carica parviflora Nutrition 0.000 claims abstract description 10
- 241000242757 Anthozoa Species 0.000 claims abstract description 8
- 229950007002 phosphocreatine Drugs 0.000 claims abstract description 7
- 239000003446 ligand Substances 0.000 claims abstract description 6
- 230000037326 chronic stress Effects 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- 230000035882 stress Effects 0.000 claims description 25
- 235000001014 amino acid Nutrition 0.000 claims description 24
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 22
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 22
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 22
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 22
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 22
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 22
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 22
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 21
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 21
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 229910021645 metal ion Inorganic materials 0.000 claims description 17
- 239000001166 ammonium sulphate Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 229920005654 Sephadex Polymers 0.000 claims description 10
- 239000012507 Sephadex™ Substances 0.000 claims description 10
- 238000001962 electrophoresis Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 150000002894 organic compounds Chemical class 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 9
- 238000002523 gelfiltration Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- 150000004665 fatty acids Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000009738 saturating Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- 239000002198 insoluble material Substances 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 235000016804 zinc Nutrition 0.000 claims description 6
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 5
- 241000243321 Cnidaria Species 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- 208000013200 Stress disease Diseases 0.000 claims description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 5
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000013793 astaxanthin Nutrition 0.000 claims description 5
- 239000001168 astaxanthin Substances 0.000 claims description 5
- 229940022405 astaxanthin Drugs 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 4
- 239000007979 citrate buffer Substances 0.000 claims description 4
- 230000019771 cognition Effects 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000001924 fatty-acyl group Chemical group 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 229960002591 hydroxyproline Drugs 0.000 claims description 4
- 230000013016 learning Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 102000016938 Catalase Human genes 0.000 claims description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 239000011435 rock Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 229940032362 superoxide dismutase Drugs 0.000 claims 4
- 238000000227 grinding Methods 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 108030002440 Catalase peroxidases Proteins 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- 230000006851 antioxidant defense Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 2
- 229910052720 vanadium Inorganic materials 0.000 claims 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 238000004078 waterproofing Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 34
- 108090000623 proteins and genes Proteins 0.000 abstract description 34
- 238000002955 isolation Methods 0.000 abstract description 9
- 230000000975 bioactive effect Effects 0.000 abstract description 5
- 230000008827 biological function Effects 0.000 abstract description 4
- 159000000032 aromatic acids Chemical class 0.000 abstract description 3
- 229930182558 Sterol Natural products 0.000 abstract description 2
- 239000012634 fragment Substances 0.000 abstract description 2
- 150000003432 sterols Chemical class 0.000 abstract description 2
- 235000003702 sterols Nutrition 0.000 abstract description 2
- 101150087322 DCPS gene Proteins 0.000 abstract 1
- 101100386724 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nhm1 gene Proteins 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 31
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 22
- 241000700159 Rattus Species 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 19
- 239000003826 tablet Substances 0.000 description 18
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 15
- 239000000470 constituent Substances 0.000 description 15
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 15
- 229940088594 vitamin Drugs 0.000 description 13
- 239000011782 vitamin Substances 0.000 description 13
- 230000003859 lipid peroxidation Effects 0.000 description 12
- 229930003231 vitamin Natural products 0.000 description 12
- 235000013343 vitamin Nutrition 0.000 description 12
- 150000003722 vitamin derivatives Chemical class 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000004367 Lipase Substances 0.000 description 11
- 102000004882 Lipase Human genes 0.000 description 11
- 108090001060 Lipase Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 229940040461 lipase Drugs 0.000 description 11
- 235000019421 lipase Nutrition 0.000 description 11
- 108010083590 Apoproteins Proteins 0.000 description 10
- 102000006410 Apoproteins Human genes 0.000 description 10
- 235000010323 ascorbic acid Nutrition 0.000 description 10
- 239000011668 ascorbic acid Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229960003624 creatine Drugs 0.000 description 10
- 229940011671 vitamin b6 Drugs 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000006046 creatine Substances 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 229940093499 ethyl acetate Drugs 0.000 description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 229960005150 glycerol Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 235000009697 arginine Nutrition 0.000 description 7
- 238000004040 coloring Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229960002477 riboflavin Drugs 0.000 description 7
- 235000019155 vitamin A Nutrition 0.000 description 7
- 239000011719 vitamin A Substances 0.000 description 7
- 229940045997 vitamin a Drugs 0.000 description 7
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 6
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 5
- 241000237852 Mollusca Species 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940072107 ascorbate Drugs 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 5
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 5
- 235000019192 riboflavin Nutrition 0.000 description 5
- 239000002151 riboflavin Substances 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical compound [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 4
- 229910052683 pyrite Inorganic materials 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 3
- 241001147665 Foraminifera Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 3
- 241000058902 Nummulites Species 0.000 description 3
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001313866 Telescopium Species 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 229940067596 butylparaben Drugs 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- CCTIOCVIZPCTGO-BYPYZUCNSA-N phosphoarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NP(O)(O)=O CCTIOCVIZPCTGO-BYPYZUCNSA-N 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 239000011028 pyrite Substances 0.000 description 3
- 239000007845 reactive nitrogen species Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 235000008210 xanthophylls Nutrition 0.000 description 3
- 150000003735 xanthophylls Chemical class 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KUKJHGXXZWHSBG-WBGSEQOASA-N 12S-HHTrE Chemical compound CCCCC[C@H](O)\C=C\C=C\C\C=C/CCCC(O)=O KUKJHGXXZWHSBG-WBGSEQOASA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 2
- FHYNZKLNCPUNEU-UHFFFAOYSA-N 4-[(3,4-dihydroxyphenyl)methyl]-3-[(4-hydroxyphenyl)methyl]oxolan-2-one Chemical compound C1=CC(O)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(O)=C1 FHYNZKLNCPUNEU-UHFFFAOYSA-N 0.000 description 2
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 2
- KGIJOOYOSFUGPC-XRXZHELTSA-N 5-hydroxyeicosatetraenoic acid Natural products CCCCCC=CCC=CCC=C\C=C\C(O)CCCC(O)=O KGIJOOYOSFUGPC-XRXZHELTSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000007716 Citrus aurantium Nutrition 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- QOEHNLSDMADWEF-UHFFFAOYSA-N I-Dotriacontanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO QOEHNLSDMADWEF-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 230000000026 anti-ulcerogenic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- WGKSVGIFYJXABK-UHFFFAOYSA-L copper;decanedioate Chemical compound [Cu+2].[O-]C(=O)CCCCCCCCC([O-])=O WGKSVGIFYJXABK-UHFFFAOYSA-L 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 2
- QHMGJGNTMQDRQA-UHFFFAOYSA-N dotriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC QHMGJGNTMQDRQA-UHFFFAOYSA-N 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 239000002509 fulvic acid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- 210000000087 hemolymph Anatomy 0.000 description 2
- SCQWVCOZCILOSS-UHFFFAOYSA-N hentetracontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO SCQWVCOZCILOSS-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960005436 inositol nicotinate Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 235000021400 peanut butter Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229940057874 phenyl trimethicone Drugs 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108020001775 protein parts Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000008684 selective degradation Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical class [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 229940053446 vitamin E d-alpha Drugs 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RSYSVNVHLXTDIR-ZZMNMWMASA-L (2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate;manganese(2+) Chemical compound [Mn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] RSYSVNVHLXTDIR-ZZMNMWMASA-L 0.000 description 1
- RZALONVQKUWRRY-XOJLQXRJSA-N (2r,3r)-2,3-dihydroxybutanedioate;hydron;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-XOJLQXRJSA-N 0.000 description 1
- FGNPLIQZJCYWLE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound OS(O)(=O)=O.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FGNPLIQZJCYWLE-BTVCFUMJSA-N 0.000 description 1
- VXVKGIZYLHTHMR-WCCKRBBISA-N (2s)-2-amino-4-methylselanylbutanoic acid;selenium Chemical compound [Se].C[Se]CC[C@H](N)C(O)=O VXVKGIZYLHTHMR-WCCKRBBISA-N 0.000 description 1
- YHHHHJCAVQSFMJ-FNORWQNLSA-N (3e)-deca-1,3-diene Chemical compound CCCCCC\C=C\C=C YHHHHJCAVQSFMJ-FNORWQNLSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- GKBHKNPLNHLYHT-LCAPWBFGSA-N (8r,9s,10s,13r,14s,17r)-17-[(2r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(CC)C(C)C)[C@@]1(C)CC2 GKBHKNPLNHLYHT-LCAPWBFGSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- JSOVGYMVTPPEND-UHFFFAOYSA-N 16-methylheptadecyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)(C)C JSOVGYMVTPPEND-UHFFFAOYSA-N 0.000 description 1
- NBIBDIKAOBCFJN-UHFFFAOYSA-N 2,2-dihydroxy-1-phenylethanone Chemical compound OC(O)C(=O)C1=CC=CC=C1 NBIBDIKAOBCFJN-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- YBPUBXQZBUQACE-UHFFFAOYSA-N 2-aminoacetic acid;phosphoric acid Chemical compound NCC(O)=O.OP(O)(O)=O YBPUBXQZBUQACE-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical class OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- UDZMHVWZLRBHMW-UHFFFAOYSA-N 4-(4-aminophenyl)aniline;periodic acid Chemical compound OI(=O)(=O)=O.C1=CC(N)=CC=C1C1=CC=C(N)C=C1 UDZMHVWZLRBHMW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000021317 Annona cherimola Species 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000258971 Brachiopoda Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- CCNVOOPOTUJXGW-UHFFFAOYSA-N C(CCC)NC(OC#CCI)=O.O(C1=CC=CC=C1)C(C)O Chemical compound C(CCC)NC(OC#CCI)=O.O(C1=CC=CC=C1)C(C)O CCNVOOPOTUJXGW-UHFFFAOYSA-N 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 241000688200 Cingulata Species 0.000 description 1
- QCZAWDGAVJMPTA-RNFRBKRXSA-N ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C Chemical compound ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C QCZAWDGAVJMPTA-RNFRBKRXSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000239250 Copepoda Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000029809 Diploria Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 241000243320 Hydrozoa Species 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CMHMMKSPYOOVGI-UHFFFAOYSA-N Isopropylparaben Chemical compound CC(C)OC(=O)C1=CC=C(O)C=C1 CMHMMKSPYOOVGI-UHFFFAOYSA-N 0.000 description 1
- 241000256602 Isoptera Species 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 241000545042 Loligo sp. Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000087774 Macrocera Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 229910015227 MoCl3 Inorganic materials 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 241001481166 Nautilus Species 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000199627 Rhynchonelliformea Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241001022751 Stylaster Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241001265087 Trichys Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- VBJLELIVBXZJIG-UHFFFAOYSA-N acetic acid octyl 2-methoxy-3-phenylprop-2-enoate Chemical compound CC(O)=O.CCCCCCCCOC(=O)C(OC)=CC1=CC=CC=C1 VBJLELIVBXZJIG-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000021336 beef liver Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019209 bilberry extract Nutrition 0.000 description 1
- 229940102480 bilberry extract Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000010474 borage seed oil Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229910000361 cobalt sulfate Inorganic materials 0.000 description 1
- 229940044175 cobalt sulfate Drugs 0.000 description 1
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical class CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229940115134 folic acid 0.04 mg Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229940058271 heme iron polypeptide Drugs 0.000 description 1
- WZHKDGJSXCTSCK-UHFFFAOYSA-N hept-3-ene Chemical compound CCCC=CCC WZHKDGJSXCTSCK-UHFFFAOYSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000215 hyperchromic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229940113094 isopropylparaben Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229910052960 marcasite Inorganic materials 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- ZSSVQAGPXAAOPV-UHFFFAOYSA-K molybdenum trichloride Chemical compound Cl[Mo](Cl)Cl ZSSVQAGPXAAOPV-UHFFFAOYSA-K 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960001682 n-acetyltyrosine Drugs 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940088175 niacinamide 10 mg Drugs 0.000 description 1
- 229940089784 niacinamide 20 mg Drugs 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007128 oxidoreductase reaction Methods 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940047208 pyridoxine 10 mg Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019191 thiamine mononitrate Nutrition 0.000 description 1
- 229960004860 thiamine mononitrate Drugs 0.000 description 1
- 239000011748 thiamine mononitrate Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- AUALKMYBYGCYNY-UHFFFAOYSA-E triazanium;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [NH4+].[NH4+].[NH4+].[Fe+3].[Fe+3].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O AUALKMYBYGCYNY-UHFFFAOYSA-E 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 229910052882 wollastonite Inorganic materials 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- ROUREIAZUKQVBD-FHNDMYTFSA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate;hydrogen sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O.CSCC[C@H](N)C(O)=O ROUREIAZUKQVBD-FHNDMYTFSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
A composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g.,carotenoids, sterols and aromatic acids, as core structural fragments, and their biological functions. Pharmaceutical, nutritional, skin care and personal care formulations are also described. These findings establish DCPs as the major bioactives of shilajit.
Description
OXYGENATED DIBENZO-ALPHA-PYRONE CHROMOPROTEINS
Cross-Reference to Related Application This application is a continuation-in-part application of U.S. Patent Application No. 10/799,104, filed March 12, 2004, entitled Oxygenated Dibenzo Alpha-Pyrone Chromoproteins, incorporated as reference in its entirety into this application.
Background of the Invention 1. Field of the Invention This invention relates to the composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, the invention relates to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g.,carotenoids, sterols and aromatic acids, as core structural fragments, and their biological functions. Pharmaceutical, nutritional, veterinary, skin care and personal care formulations are also described. These findings establish DCPs as the major bioactives of shilajit.
Cross-Reference to Related Application This application is a continuation-in-part application of U.S. Patent Application No. 10/799,104, filed March 12, 2004, entitled Oxygenated Dibenzo Alpha-Pyrone Chromoproteins, incorporated as reference in its entirety into this application.
Background of the Invention 1. Field of the Invention This invention relates to the composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, the invention relates to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g.,carotenoids, sterols and aromatic acids, as core structural fragments, and their biological functions. Pharmaceutical, nutritional, veterinary, skin care and personal care formulations are also described. These findings establish DCPs as the major bioactives of shilajit.
2. Description of the Related Art There are probably thousands of carotenoproteins to be found in nature.
However, even today structures of a very few such compounds have been fully characterized by applying the techniques of protein chemistry. Partial analysis has shown that among these compounds there are many lipoproteins in which the carotenoid moieties appear to be associated also with the lipid component.
However, a stoichiometric relationship between carotenoid and protein has not always been found.
This application is related to U.S. Patent Nos. 6,440,436 B1 and 6,558,712 B1 by the same inventor, which are each incorporated by reference herein.
In many pigmented proteins found in marine invertebrates, - living and fossilized, carotenoids and other coloured compounds (e.g., pyrroloids, biliverdin and indigoids, - indigotin and indirubin) are found to show interaction with the protein part as well as association with the lipid prosthetic group of the complex assembly.
But never before has the presence of Oxygenated Dibenzo-alpha-pyrone (DBPs), wherein there is an oxygen linker attached at the 3 and/or 8-position of the DBP, in either free form or in association with chromoproteins, in living or fossilized marine invertebrates, been reported. The present invention describes one such class of pigmented proteins, named dibenzo-alpha-pyronechromoproteins (abbreviated as DCPs), isolated in large abundance, from shilajit, fossils of ammonites, corals and $ other marine invertebrates.
Summary of the Invention The present invention relates to compositions of DCPs, isolation, and their use in treating various adaptogenic conditions, such as chronic stress.
In one embodiment, the invention provides a composition of dibenzo-alpha-pyrone-chromoproteins (DCPs) which include dibenzo-alpha-pyrone or their derivatives; Phosphocreatine; Chromo-peptides of molecular weights of < 2 KD;
and Lipids having fatty acyl esters of glycerol.
Another embodiment of the invention includes dibenzo-alpha-pyrones of formula (I) R
R
R
R
1$
(I) wherein:
R1 is selected from the group consisting of H, OH, O-acyl, and O-amino-acyl;
and R5, R6, R', R8, R9, and R~° are independently selected from the group consisting of H, OH, O-acyl, O-amino-acyl, and fatty acyl groups.
Another embodiment of the invention includes a composition wherein phosphocreatine is attached to the 3- or 8-position of said dibenzo-alpha-pyrones via an ester linkage. Also, the chromo-peptides include one or more amino acids;
However, even today structures of a very few such compounds have been fully characterized by applying the techniques of protein chemistry. Partial analysis has shown that among these compounds there are many lipoproteins in which the carotenoid moieties appear to be associated also with the lipid component.
However, a stoichiometric relationship between carotenoid and protein has not always been found.
This application is related to U.S. Patent Nos. 6,440,436 B1 and 6,558,712 B1 by the same inventor, which are each incorporated by reference herein.
In many pigmented proteins found in marine invertebrates, - living and fossilized, carotenoids and other coloured compounds (e.g., pyrroloids, biliverdin and indigoids, - indigotin and indirubin) are found to show interaction with the protein part as well as association with the lipid prosthetic group of the complex assembly.
But never before has the presence of Oxygenated Dibenzo-alpha-pyrone (DBPs), wherein there is an oxygen linker attached at the 3 and/or 8-position of the DBP, in either free form or in association with chromoproteins, in living or fossilized marine invertebrates, been reported. The present invention describes one such class of pigmented proteins, named dibenzo-alpha-pyronechromoproteins (abbreviated as DCPs), isolated in large abundance, from shilajit, fossils of ammonites, corals and $ other marine invertebrates.
Summary of the Invention The present invention relates to compositions of DCPs, isolation, and their use in treating various adaptogenic conditions, such as chronic stress.
In one embodiment, the invention provides a composition of dibenzo-alpha-pyrone-chromoproteins (DCPs) which include dibenzo-alpha-pyrone or their derivatives; Phosphocreatine; Chromo-peptides of molecular weights of < 2 KD;
and Lipids having fatty acyl esters of glycerol.
Another embodiment of the invention includes dibenzo-alpha-pyrones of formula (I) R
R
R
R
1$
(I) wherein:
R1 is selected from the group consisting of H, OH, O-acyl, and O-amino-acyl;
and R5, R6, R', R8, R9, and R~° are independently selected from the group consisting of H, OH, O-acyl, O-amino-acyl, and fatty acyl groups.
Another embodiment of the invention includes a composition wherein phosphocreatine is attached to the 3- or 8-position of said dibenzo-alpha-pyrones via an ester linkage. Also, the chromo-peptides include one or more amino acids;
carotenoids; and indigoids. The chromo-proteins have a molecular weight of about 2 to about 20 KD.
Another embodiment of the invention provides a skin care, hair care, pharmaceutical, veterinary or nutritional formulation comprising a DCP
composition present in an amount of about 0.05% to about 50% by weight. Also, the skin care or protection formulation can be in the form of a lotion, cream, gel or spray, wherein the DCP composition is present in an amount of about 0.05% to about 5% by weight.
Another embodiment of the invention provides a pharmaceutical formulation comprising a DCP composition wherein the pharmaceutical formulation is in the form of a tablet, syrup, elixir or capsule.
Another embodiment of the invention provides a nutritional formulation comprising a DCP composition wherein the nutritional formulation contains about 0.5% to about 30% of the DCP composition by weight.
Another embodiment of the invention provides a veterinary formulation comprising a DCP composition wherein the veterinary formulation contains about 0.5% to about 30% of the DCP composition by weight.
Another embodiment of the invention provides a process for isolating DCP
compositions from shilajit compositions comprising about 0.5% to about 10% w/w dibenzo-alpha-pyronechromoproteins, the process includes the steps of 1)extracting shilajit successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration; 2) triturating the ethyl acetate and methanol insoluble material with hot water and then citrate buffer of pH 5.0; 3) filtering the combined extract-mixture to remove insoluble substances comprising polymeric humic materials, minerals and metal ion salts; 4) gradually saturating the combined aqueous filtrate with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating the combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering the DCPs and evaporating the filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and S) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from shilajit.
Another embodiment of the invention provides a skin care, hair care, pharmaceutical, veterinary or nutritional formulation comprising a DCP
composition present in an amount of about 0.05% to about 50% by weight. Also, the skin care or protection formulation can be in the form of a lotion, cream, gel or spray, wherein the DCP composition is present in an amount of about 0.05% to about 5% by weight.
Another embodiment of the invention provides a pharmaceutical formulation comprising a DCP composition wherein the pharmaceutical formulation is in the form of a tablet, syrup, elixir or capsule.
Another embodiment of the invention provides a nutritional formulation comprising a DCP composition wherein the nutritional formulation contains about 0.5% to about 30% of the DCP composition by weight.
Another embodiment of the invention provides a veterinary formulation comprising a DCP composition wherein the veterinary formulation contains about 0.5% to about 30% of the DCP composition by weight.
Another embodiment of the invention provides a process for isolating DCP
compositions from shilajit compositions comprising about 0.5% to about 10% w/w dibenzo-alpha-pyronechromoproteins, the process includes the steps of 1)extracting shilajit successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration; 2) triturating the ethyl acetate and methanol insoluble material with hot water and then citrate buffer of pH 5.0; 3) filtering the combined extract-mixture to remove insoluble substances comprising polymeric humic materials, minerals and metal ion salts; 4) gradually saturating the combined aqueous filtrate with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating the combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering the DCPs and evaporating the filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and S) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from shilajit.
Another embodiment of the invention provides similar processes for extracting and isolating DCPs from fossils of ammonites, fossils of corals, and from other living and nonliving invertebrates.
Another embodiment provides a method for treating chronic stress disorders, including administering to a patient in need thereof a therapeutically effective amount of a DCP composition and a method for increasing cognition learning which includes administering a DCP composition.
Brief Description of the Drawings Fig. 1A and 1B show the general structure of DCPs and the conjugate assembly of DCPs.
Fig. 2 shows changes in different DCP levels with time in red blood cells of DCP-fed albino rats.
Fig. 3 shows HPLC chromatograms of Shilajit DCPs from ammonium sulphate precipitations.
1 S Fig. 4 shows the relationship between 3, 8-dihydroxy dibenzo-alpha-pyrones and protein fractions.
Detailed Description of the Invention DCPs, comprising organo-mineral constituents exhibit orange, purple and yellow colors contributed by oxygenated carotenoids known as xanthophylls and indigoids derived from systemic oxidation of tryptophan moieties. The DCPs of shilajit exhibit absorption maxima in the UV and visible regions at ~, 225, 275, 320, ~ 392, ~ 470, ~ 492, 500-535, 620-660 nm. An aqueous solution of the DCPs, spread on silica gel having 230-400 mesh, when heated by micro-wave resulted in partial dissociation of carotenoids. The identities of the colored compounds were established by HPLC using authentic markers. The apoprotein part, obtained from this reaction, however, still retained much of the coloring moieties. On gel filtration of the partially degraded protein, and subsequent analysis (e.g.,chemical, chromatographic and spectroscopic), of the isolated compounds revealed the presence of a large prosthetic group, particularly rich in DBPs and equivalents.
Selective lipase degradation of the products, liberated DBPs, phospholipids (containing C,4-C24 fatty acids, both saturated and unsaturated), and partially cleaved the proteins into chromo-lipoproteins and chromo-apoproteins. Even harsh acidic hydrolysis could not completely detach the nitrogenous constituents from the DBP-nucleus. Thus, the conjugated proteins containing both less polar and more polar fractions still retained some of the amino acids/ small peptides, xanthophylls and indigoids, as determined by HPLC of the degraded products, in the lipase degradation products and some amino acid/ small peptide in the conjugate DBPs even after 5 classical acidic hydrolysis.
On saponification, DCPs produced free DBPs and small conjugated DBP
metabolites, fatty acids and amino acids. The facile removal of the acylated compounds by saponification suggested that some aminoacyl and fatty acyl moieties are attached to the phenolic hydroxyl groups) of DBPs. Additionally, the occurrence of small O-acyl conjugates of amino acids in 3-OH-DBP from 3-O-acyl glycinoyl and 3-O-acyl arginoyl DBPs, and also creatine in DCPs support the DBP-prosthetic group structure of the DCPs shown in Formula 1.
R~~
Chromo-peptides R~
Hz R' O-CHz-H-CO~
O I I CHz- ~ -I I-N- ~ --~ O
O Rz NH O-CHz-C-CHz I I
Phosphocreatine R R
Lipids Formula 1 wherein:
R' = H, OH, O-acyl, O-amino acyl, or di- or tri-peptides of these aminoacids;
RZ = H or CH3;
Another embodiment provides a method for treating chronic stress disorders, including administering to a patient in need thereof a therapeutically effective amount of a DCP composition and a method for increasing cognition learning which includes administering a DCP composition.
Brief Description of the Drawings Fig. 1A and 1B show the general structure of DCPs and the conjugate assembly of DCPs.
Fig. 2 shows changes in different DCP levels with time in red blood cells of DCP-fed albino rats.
Fig. 3 shows HPLC chromatograms of Shilajit DCPs from ammonium sulphate precipitations.
1 S Fig. 4 shows the relationship between 3, 8-dihydroxy dibenzo-alpha-pyrones and protein fractions.
Detailed Description of the Invention DCPs, comprising organo-mineral constituents exhibit orange, purple and yellow colors contributed by oxygenated carotenoids known as xanthophylls and indigoids derived from systemic oxidation of tryptophan moieties. The DCPs of shilajit exhibit absorption maxima in the UV and visible regions at ~, 225, 275, 320, ~ 392, ~ 470, ~ 492, 500-535, 620-660 nm. An aqueous solution of the DCPs, spread on silica gel having 230-400 mesh, when heated by micro-wave resulted in partial dissociation of carotenoids. The identities of the colored compounds were established by HPLC using authentic markers. The apoprotein part, obtained from this reaction, however, still retained much of the coloring moieties. On gel filtration of the partially degraded protein, and subsequent analysis (e.g.,chemical, chromatographic and spectroscopic), of the isolated compounds revealed the presence of a large prosthetic group, particularly rich in DBPs and equivalents.
Selective lipase degradation of the products, liberated DBPs, phospholipids (containing C,4-C24 fatty acids, both saturated and unsaturated), and partially cleaved the proteins into chromo-lipoproteins and chromo-apoproteins. Even harsh acidic hydrolysis could not completely detach the nitrogenous constituents from the DBP-nucleus. Thus, the conjugated proteins containing both less polar and more polar fractions still retained some of the amino acids/ small peptides, xanthophylls and indigoids, as determined by HPLC of the degraded products, in the lipase degradation products and some amino acid/ small peptide in the conjugate DBPs even after 5 classical acidic hydrolysis.
On saponification, DCPs produced free DBPs and small conjugated DBP
metabolites, fatty acids and amino acids. The facile removal of the acylated compounds by saponification suggested that some aminoacyl and fatty acyl moieties are attached to the phenolic hydroxyl groups) of DBPs. Additionally, the occurrence of small O-acyl conjugates of amino acids in 3-OH-DBP from 3-O-acyl glycinoyl and 3-O-acyl arginoyl DBPs, and also creatine in DCPs support the DBP-prosthetic group structure of the DCPs shown in Formula 1.
R~~
Chromo-peptides R~
Hz R' O-CHz-H-CO~
O I I CHz- ~ -I I-N- ~ --~ O
O Rz NH O-CHz-C-CHz I I
Phosphocreatine R R
Lipids Formula 1 wherein:
R' = H, OH, O-acyl, O-amino acyl, or di- or tri-peptides of these aminoacids;
RZ = H or CH3;
R3 = H or Cla - Cza saturated or unsaturated fatty acid; degree of unsaturation ranging from one to six;
Ra = H or C,a - Cza saturated or unsaturated fatty acid; degree of unsaturation ranging from one to six; and S R5, R6, R', Rg, R9, and Rl° are independently selected from the group consisting of H, OH, O-acyl, O-amino-acyl, and fatty acyl groups.
The chromo-proteins have a weight of 2-20 kilodaltons (KD), and include but are not limited to amino acids, di- and tri-peptides of these aminoacids, carotenoids and indigoids.
Acyclic and cyclic carotenoids or xanthophylls and indigoids, such as lutein, astaxanthin, and beta-carotene are pigments.
Fatty acids may be branched or unbranched and contain carbon atoms between 14 and 24, and may be either saturated or unsaturated. The degree of unsaturation is between one and six.
Degree of unsaturation is the number of double bonds present.
Acyl is -COR where R may be branched or unbranched and contain carbon atoms between 16 and 18, and may be either saturated or unsaturated.
Amino acids include but are not limited to alanine, arginine, creatine, glycine, hydroxyproline, methionine, proline, serine, threonine, and tryptophan.
A dipeptide results when an amide bond is formed between the -NHz of one amino acid and the -COOH of a second amino acid; a tripeptide results from linkage of three amino acids via two amide bonds, and so on. Any number of amino acids can link together to form large chains.
The numbering pattern of the dibenzo-alpha-pyrone is as follows:
~1 R1o (9 (s) Rs ~ (7) (io) (6) R
s R O(;
(~) ~ I
I (a) R~ (2~ (3) Rs The presence of creatine in DCPs was established by both in vivo and in vitro determinations.
The chromo-moieties in DCPs were found to be associated with both the apolar lipid as well as the polar protein fractions. Lipase degradation followed by characterization of the degraded parts and HPLC analysis showed that the chromo-compounds were attached to the two different fractions albeit in different state of binding. The protein part on further acid hydrolysis produced methionine, arginine, glycine, alanine, serine, threonine, proline and hydroxyproline as the identifiable amino acids.
DCPs contain proteins of molecular weight with a range between 2 to about 20 KD. Separation of DCPs into three bands by polyacrylamide gel electrophoresis (PAGE) revealed that conjugated proteins of molecular weight between about 15 to about 20 KD are present in higher amount than about 2 to about 12 KD. But conjugated protein of molecular weight range about 12 to about 15 KD is present in lowest amount.
During elucidating the structures of DCPs, the following striking differences were discerned between the DCPs isolated from shilajit and those from shilajit-precursor-invertebrates:
1. DCPs, in which the apoprotein is colorless, and the colored compounds containing long prosthetic groups (e.g., DBPs and lipids), can be dissociated by simple treatment of aqueous solution of DCPs, either with acetone or ethyl alcohol.
The colorless apoproteins exhibit simple HPLC patterns and on acid hydrolysis produced, apart from DBPs and conjugates, the amino acids described above.
These DCPs, isolated from fossils of Ammonites, are readily split into the colorless apoproteins and coloring matter, which are soluble in the extracted organic solvents.
2. The other class constitutes DCPs in which the coloring matter comprising carotenoids and indigoids are ordinarily undissociable from the apoprotein. This class of DCPs was isolated from shilajit and from some rare species of fossils of Ammonites (e.g., Perisphinctes with red protoconch) Proteins of some invertebrates spread at the air/water interface with extreme reluctance. The apoproteins, when dissociated from the prosthetic groups (e.g., containing the coloring matter such as carotenoids), spread smoothly during electrophoresis. The carotenoids in such chromo-proteins seem to act as a 'lock' on the tertiary or quaternary structure of the proteins against denaturation. The colorless apoproteins, formed from dissociation of chromoproteins, by contrast undergo immediate coagulation and partial denaturation.
In shilajit-DCPs the association of the chromo-molecules and the apoproteins are not, ordinarily, dissociable. A specific, tenacious, combination of the two moieties is conceivable. Consistent with this postulate, the chromo-compounds in shilajit-DCPs were found to be associated with both the lipid and apoprotein fractions.
Selective degradation of DCPs with lipase, followed by HPLC established this point.
The stable quaternary structure of the shilajit-DCPs was further suggested by the following experiment. When subjected to electrophoresis in starch-urea gels, two chromoproteins, DCP-I, which is orange-pink in color (Mw < 5 KD) and DCP-II, which is yellowish-brown in color (containing appreciably larger abundance of DBPs than are present in DCP-I; Mw < 14 KD), were separated. These properties suggest that some coloring (pigment) molecules are covalently linked with some parts of the apoproteins and lipo-protein components. A close association between the amino acid moieties, capable of interaction with the carotenoids and indigoids would provide the strength of the association, which in fact is reflected in the profound bathochromic shift (~ ~, 500 nm to ~, 660 nm) and hyperchromic effect in the visible spectrum of DCP colored chromophores.
Based on the above, the general structure of DCPs (FIGURE 1A) and the conjugate assembly of DCPs (FIGURE 1B) were assigned.
The protein content of DCPs, estimated by Lowry's method, was 57.13%;
whereas, by the Bradford method it was 59.3%. The higher percentage of protein, estimated by the latter method, was presumably due to its higher sensitivity to the appreciable content of arginine in the DCPs.
Portions of the lipid moieties present in the Formula 1 are covalently linked with the prosthetic group(s). This was suggested by the following study.
Exhaustive extractions of DCPs by Bligh and Dyer solvent system, suitable for extraction of lipids, did not yield any free fatty acid but gave a small amount of acylated DCPs.
The major insoluble residue on reaction with lipase produced C14 to C24 fatty acids in which C 16:0 C 18:0 and C 1 g; l were the main components as depicted in Table 1.
Thus, lipoproteins seem to constitute an integral part of the DCPs.
Ra = H or C,a - Cza saturated or unsaturated fatty acid; degree of unsaturation ranging from one to six; and S R5, R6, R', Rg, R9, and Rl° are independently selected from the group consisting of H, OH, O-acyl, O-amino-acyl, and fatty acyl groups.
The chromo-proteins have a weight of 2-20 kilodaltons (KD), and include but are not limited to amino acids, di- and tri-peptides of these aminoacids, carotenoids and indigoids.
Acyclic and cyclic carotenoids or xanthophylls and indigoids, such as lutein, astaxanthin, and beta-carotene are pigments.
Fatty acids may be branched or unbranched and contain carbon atoms between 14 and 24, and may be either saturated or unsaturated. The degree of unsaturation is between one and six.
Degree of unsaturation is the number of double bonds present.
Acyl is -COR where R may be branched or unbranched and contain carbon atoms between 16 and 18, and may be either saturated or unsaturated.
Amino acids include but are not limited to alanine, arginine, creatine, glycine, hydroxyproline, methionine, proline, serine, threonine, and tryptophan.
A dipeptide results when an amide bond is formed between the -NHz of one amino acid and the -COOH of a second amino acid; a tripeptide results from linkage of three amino acids via two amide bonds, and so on. Any number of amino acids can link together to form large chains.
The numbering pattern of the dibenzo-alpha-pyrone is as follows:
~1 R1o (9 (s) Rs ~ (7) (io) (6) R
s R O(;
(~) ~ I
I (a) R~ (2~ (3) Rs The presence of creatine in DCPs was established by both in vivo and in vitro determinations.
The chromo-moieties in DCPs were found to be associated with both the apolar lipid as well as the polar protein fractions. Lipase degradation followed by characterization of the degraded parts and HPLC analysis showed that the chromo-compounds were attached to the two different fractions albeit in different state of binding. The protein part on further acid hydrolysis produced methionine, arginine, glycine, alanine, serine, threonine, proline and hydroxyproline as the identifiable amino acids.
DCPs contain proteins of molecular weight with a range between 2 to about 20 KD. Separation of DCPs into three bands by polyacrylamide gel electrophoresis (PAGE) revealed that conjugated proteins of molecular weight between about 15 to about 20 KD are present in higher amount than about 2 to about 12 KD. But conjugated protein of molecular weight range about 12 to about 15 KD is present in lowest amount.
During elucidating the structures of DCPs, the following striking differences were discerned between the DCPs isolated from shilajit and those from shilajit-precursor-invertebrates:
1. DCPs, in which the apoprotein is colorless, and the colored compounds containing long prosthetic groups (e.g., DBPs and lipids), can be dissociated by simple treatment of aqueous solution of DCPs, either with acetone or ethyl alcohol.
The colorless apoproteins exhibit simple HPLC patterns and on acid hydrolysis produced, apart from DBPs and conjugates, the amino acids described above.
These DCPs, isolated from fossils of Ammonites, are readily split into the colorless apoproteins and coloring matter, which are soluble in the extracted organic solvents.
2. The other class constitutes DCPs in which the coloring matter comprising carotenoids and indigoids are ordinarily undissociable from the apoprotein. This class of DCPs was isolated from shilajit and from some rare species of fossils of Ammonites (e.g., Perisphinctes with red protoconch) Proteins of some invertebrates spread at the air/water interface with extreme reluctance. The apoproteins, when dissociated from the prosthetic groups (e.g., containing the coloring matter such as carotenoids), spread smoothly during electrophoresis. The carotenoids in such chromo-proteins seem to act as a 'lock' on the tertiary or quaternary structure of the proteins against denaturation. The colorless apoproteins, formed from dissociation of chromoproteins, by contrast undergo immediate coagulation and partial denaturation.
In shilajit-DCPs the association of the chromo-molecules and the apoproteins are not, ordinarily, dissociable. A specific, tenacious, combination of the two moieties is conceivable. Consistent with this postulate, the chromo-compounds in shilajit-DCPs were found to be associated with both the lipid and apoprotein fractions.
Selective degradation of DCPs with lipase, followed by HPLC established this point.
The stable quaternary structure of the shilajit-DCPs was further suggested by the following experiment. When subjected to electrophoresis in starch-urea gels, two chromoproteins, DCP-I, which is orange-pink in color (Mw < 5 KD) and DCP-II, which is yellowish-brown in color (containing appreciably larger abundance of DBPs than are present in DCP-I; Mw < 14 KD), were separated. These properties suggest that some coloring (pigment) molecules are covalently linked with some parts of the apoproteins and lipo-protein components. A close association between the amino acid moieties, capable of interaction with the carotenoids and indigoids would provide the strength of the association, which in fact is reflected in the profound bathochromic shift (~ ~, 500 nm to ~, 660 nm) and hyperchromic effect in the visible spectrum of DCP colored chromophores.
Based on the above, the general structure of DCPs (FIGURE 1A) and the conjugate assembly of DCPs (FIGURE 1B) were assigned.
The protein content of DCPs, estimated by Lowry's method, was 57.13%;
whereas, by the Bradford method it was 59.3%. The higher percentage of protein, estimated by the latter method, was presumably due to its higher sensitivity to the appreciable content of arginine in the DCPs.
Portions of the lipid moieties present in the Formula 1 are covalently linked with the prosthetic group(s). This was suggested by the following study.
Exhaustive extractions of DCPs by Bligh and Dyer solvent system, suitable for extraction of lipids, did not yield any free fatty acid but gave a small amount of acylated DCPs.
The major insoluble residue on reaction with lipase produced C14 to C24 fatty acids in which C 16:0 C 18:0 and C 1 g; l were the main components as depicted in Table 1.
Thus, lipoproteins seem to constitute an integral part of the DCPs.
Table-1: Fatty acids composition of four ammonium sulphate precipitated DCPs after Lipase cut.
Ammonium Arachidonic C-14 to C-20 C- to C-sulphate EPA+DHA 16:0+18:0 acid 18a 246 precipitation 25% 14.94% 4.44% 0.94% 17.95% 82.05%
50% 20.95% 10.61% 0.92% 18.17% 81.83%
7$% 0.60% 9.22% 27.28% 48.05% 51.95%
100% 0.14% 4.26% 1.28% 43.30% 56.70%
a+b = 100% of total fatty acids.
~ = Expressed as % of total fatty acids present in each sample.
Many of the shilajit-bearing mountains have been found to be rich storehouses of marine invertebrate fossils, such as of the phyla of Arthropoda, Brachiopoda and Mollusca, of the Phanerozoic era. This co-occurrence of shilajit and the invertebrate fossils, as depicted in Table 2, is a consistent phenomenon.
Table 2. Marine invertebrate (fossils and living) analyzed for DBPs and DCPs.
Age of specimen Phylum/Class: Genus, species(period) Sr Place of Occurrence No . (Order/Family) Reference/Type numbera~b Fossils Arthro oda/Trilobita:
Cambrian GSI
-I Ptychoparia spitiensis a II Asaphus s . Ordovician Brachio oda/Articulata III Kutchithyris acutiplicataJurassic GSI-6596aKutch, Gujarat Consinanthris sp. Cretaceous Trichy ,Tamil Nadu (Terebratellacea) Mollusca/Cephalo oda V Nautilus angustus Cretaceous ~ aloor TN
y ' (Ammonoidea) GSI-97425a VI Perisphinctes aberrance Jurassic Kutch GJ
(Ammonoidea) GSI-2043a VII Kamptokephalites dimerus Jurassic Kutch GJ
(Ammonoidea), female sp. JUM - 1314b Jurassic VIII K. dimerus, male sp. b Kutch, GJ
Idiocyclocerus perisphinctoidesJurassic Kutch GJ
(Ammonoidea), female sp. JUM-332b Jurassic X I. perisphinctoides, maleb Kutch, GJ
sp. JUM-323 XI Paryphocerus sp. Jurassic Muktinath, Nepal (Ammonoidea Foraminifera (Protozoa XII Alveolina sp. Cretaceous Kutch, Gj XIII Discocyclina sp. Paleocene, Javana, Trichi Oligocene XIV Nummulites sp. Early Miocene Kutch, Gj, Jayanthia Hill, India XV Nacutus sp. - Kutch, Gj Cnidaria/Anthozoa (coral) XVI Diploria - Bay of Bengal Cnidaria/Hydrozoa (coral) XVII Stylaster - Bay of Bengal Table 2 Continued. Marine invertebrates (living) Ph lum/Class:Age of specimen Place of Parts Sr. species (period),Reference/Type No Genus , numbera~b Occurrence examined (Order/Family) Living invertebrates - MolluscalGastropoda Coastal Telescopium region of Body X~ telescopium - Bay of flesh Bengal Coastal Cerethedia region of Body cingulata _ Bay of flesh Bengal Mollusca/Cephalopoda Coastal region of Body XXI Loligo sp. _ Bay of flesh Bengal Arthropoda/Crustacea Coastal Osipoda region of Body XXII macrocera _ Bay of flesh (Red crab) Bengal Coastal region of Body XXIII Copepoda _ Bay of flesh Bengal a Geological Survey of India, Calcutta b Geological Sciences Museum, Jadavpur University, Calcutta (through the courtesy of Prof. S. Bardhan) The remaining samples were obtained from Messrs Hindusthan Minerals, Calcutta.
Also, the organic compounds found in these fossils and in shilajit are very similar as shown in Tables 3-6.
Table-3. HPTLC data of compounds found common in marine invertebrates and shilajit Compound Developing RF Reflectance max. Mode of Solvent /nm detection 3-Hydroxy-DBP A 0.51 222, 230, 278, 300,D-Q/M-F
DBP~acyl-3,8-dihydroxy-A 0.35 218, 252, 304, 330,D-Q/M-F
3,8-Dihydroxy-DBP A 0.22 215, 236, 272, 294,D-Q/M-F
Dimeric-DBP B 0.25 215, 280, 332, 348 D-Q
Glucitol B 0.20 - T, BMP
Ribitol B 0.18 - T, BMP
Allantoin C 0.42 228, 262 D-Q
Uric acid C 0.33 222, 288 D-Q
Proline C 0.25 - T, Nin.
Hydroxyproline C 0.20 - T, Nin.
Glycine C 0.16 - T, Nin.
a the acyl moiety was constituted of C 16-C20 fatty acids Q quenching mode D deuterium lamp, wave length 260 nm M mercury lamp, wave length 360 nm; F, fluorescence mode T tungsten lamp, wave length 520 nm;
BMP, benzidine-metaperiodate staining reagent for polyols, sugars;
Nin, ninhydrin reagent for detection of amino acids Table-4. HPLC data of compounds found common in marine invertebrates and shilajit Compound Retention time PDA ~,max nm tR in min 3, 8-Dih drox -DBP 5.55 238, 295, 318, 337, dimer 375 2, 4, 6 6.22 222, 268, 318, 342 Trih drox aceto henone 2, 4- 6.41 220, 230sh, 263, 275, Dih drox acetophenome 325 3, 5- 6.50 218, 263, 315 Dih drox aceto henone Benzoic acid 8.197 228, 272 3, 8-Dih drox -DBP 10.08 238, 271, 280, 300, 3, 8-DBP- uinone 11.33 220, 230, 290, 345, Monoacyl-3, 8-dihydroxy-25.68 243, 290, 304, 342 DBPsa 3-Hydroxy-DBP 31.06 233, 271, 295, 304, C16-C20 fatty acids were detected after hydrolysis followed by GC of their methyl esters using markers Table - 5. GC-MS data of compounds found common in marine invertebrates and shilajit Compound Mol. formulaRetention time,MS : m/z tR in min Dotriacontanol C32H60O 11.032 466 M+
o - CgH1002 12.110 150(M+), 135, 107, Methox acetophenone EPA as methyl esterC21H3202 19.033 no detectable M+, fragment-ions:287, 284, 279, 274, 262, 201, 187, 105, Dotriacontane C32H66 19.048 450(M+
Oleoyl alcohol C18H360 22.751 268(M+) Hentetracontanol C41Hg40 22.899 592 M+
DHA as methyl esterC23H3402 23.150 no detectable M+, fragment- ions:
268, 262, 254, 247, 223, 219, 105, 91 Methyl-4- C1gH380 23.416 380(M+) h drox octadecanoate Tetratetracontane C44H90 23.567 618(M+
Squalene C30H50 26.56/26.716 410 (M+), 395, 367, 341, 299, 175, 149, 123, 105, 95, 69 Dinosterane C30H54 27.821 414 (M+), 301, 300, 273, 272, 177, 24-Ethylcholestane C29H52 30.042 400 (M+), 287, 286, 269, 268, 229, 117, 85 Benzamide - 5.719 193(M+), 178, 105, 77, 73 Phenylacetic acid - 6.06 208(M+), 193, 118, 91, 77 m-Hydroxybenzoic - 6.384 282 acid (as Di-TMS) (M+),267,223,193,147 ,73 -Methyl hippuric - 6.70 265 (M+), 250, acid 206, 190, 177, 105, 73, 51 6.749 208 (M+), 193, 180, H drox aceto henone 151, 105, 73 y y p Compound Mol. formulaRetention time,MS : m/z tR in min 2,4 - - 7.283 296 (M+), 281, 252, Dihydroxyacetophenon 239, 179, 73 a (as mono -TMS
Ribitol (as penta - 7.480 512 (M+), 413 (base -TMS) eak) p - Hydroxy - N - 7.666 223 (M+), 208, - 178, methyl benzamide 177 151 150 ' ' ' (as mono - TMS) 119, 73 Glucitol (as hexa-TMS)- 7.698 614 (M+), 485 (base peak , 319, 205 m - Hydroxyphenyl - 7.984 +
310 (M ), 295, 251, propionic acid (as 194, 117, 73 di -TMS) 3 - Hepten - 4 - - 9.551 390 (M+), 375 (base hydroxydioic acid peak), 259, 244, (as di-TMS) 117, 73 m - Cresol - 10.59 180 (M+ , 165, 79, 51 Uric acid (as tetra- 14.203 456 (M+), 441 (base -TMS) peak) 426, 383, 367, 147, 77, 73 3-Hydroxy-DBP - 18.702/19.851a284(M+), 269 (base peak), 241, 213, 183, 156, 94, 75 3,8- Dih drox -DBP - 23.910/25.165a372 M+ , 357, 327,73 p-Hydroxy-bis- - 32.533 344(M+), 329, 179, diphenyl methane 157, 135 (as di-TMS
Cholesterol - 36.283 458(M+), 443 (base peak), 368, 329, 247, 213, 129, 73 a GC-MS in two different conditions Table 6. Relative abundance of different groups of compoundsa found in marine invertebrate fossils and in shilajit Relative abundance Compound type Foraminiferab Molluscac Shilajitd H drocarbons 5.46 2.08 4.03 Fatt acids 15.10 14.77 11.56 Wax esters 1.33 2.05 3.88 Alk 1 g1 cerols 0.88 0.76 0.57 Alk lacyl 1 cerols 1.04 1.11 2.58 Triacylglycerols 2.11 3.54 5.03 Aromatic/phenolic 4.45 . 9.21 12.10 acids H drox aceto henones0.24 2.31 2.39 N, S-Heteroc clics 0.18 2.74 1.01 Ox genated DBPs 14.55 8.31 3.03 DBP-Chromoproteins 2.01 21.10 32.33 (DCPs Partially characterized7.22 11.60 8.64 com ds.
Humic substances (including polymeric45.43 20.42 12.85 com ds)e a By GC-MS analysis of corresponding methyl esters and TMS derivatives and other chromatographic and spectroscopic analyses b Mean of rel. abundance of compounds isolated from Nummulites, Alveolina, and Discocyclina fossils c Mean of rel. abundance of compounds isolated from fossils of Mollusca d Collected from the Kumaon region of the Himalaya Estimated by HPTLC
These findings suggest that marine invertebrates contribute to the formation of shilajit.
The marine invertebrates (Table 2) were investigated, followed by the isolation and characterization of DCPs in shilajit. Very similar DBP-carotenoproteins and other low Mw organic and coloring constituents (e.g., indigoids) were found in the marine invertebrate samples (Table 3-6).
The IR spectra of the mixture of DCPs isolated from shilajit and the Ammonites (Table 2) were similar. Also; the HPLC retention times of the major peaks and their PDA spectra were similar. The DCP-fractions on exhaustive organic solvent extractions followed by the usual work-up yielded astaxanthin, astaxanthin fatty acyl derivatives and canaxanthin. 3,8-Dihydroxy dibenzo-alpha-pyrone and the amino acids isolated from shilajit-DCPs, were also isolated from the Ammonite fossils (Table 2) from their acid hydrolysates.
The colored constituents of the DBP-chromoproteins from the Ammonites included mono-N-benzoyl indigotin, indirubin and isatin, presumably derived from the metabolism of the tryptophan moiety present in the DCPs. The browning of the proteins from the glycation of proteins, due to oxidative stress, was also discerned in the DCPs of both shilajit and the Ammonites fossils.
Preservation of color patterns on invertebrate fossils is a rare phenomenon but has been recorded throughout the Phanerozoic. The colored molecules comprising carotenoids, indigoids, and glycation of protein products, by the Maillard reaction, may form stable complexes by coordination with metal ions. Such infra-crystalline biomolecules act as a nucleation site for biomineralization. When limb muscles of dead marine animals decay, the vacated spaces are filled with minerals, such as pyrite (FeS2, CaSi03) before the thin organic cuticles that surround them have time to collapse or decay. The organic material forms a substrate for the nucleation of pyrite (and other minerals), which is ubiquitous in marine sediments. Precipitation is ensued as a result of diffusion of Fe and S into the cell. Pyrite does not replace the tissue directly but precipitates on surfaces and within spaces. Mutual stabilization of the coloured molecules and proteins in shilajit as well as in the fossils of Ammonites, was augmented by the participation of the DBPs Formula (I). This is the first demonstration of the natural occurrence of DBPs in complex association with chromoproteins. Whether this association is a general phenomenon, also in the living human and animal organisms, was also evaluated. Mixture of DCPs (pink colored) isolated from plasma of albino rats when compared with the corresponding fractions of DCPs from shilajit exhibited some striking similarities in respect of HPLC
peaks and their PDA spectra. Even greater similarities were observed between semi-purified DCP constituents by gel filtration over Sephadex G-50, obtained from shilajit and from the plasma of a human volunteer. Similar general HPLC patterns were observed with several healthy human subjects.
DCPs when administered to experimental animals showed dynamic turnover in respect of some of the key constituents (FIGURE 2). Likewise, the DBPs when administered orally (p. o.) to rat readily absorb and utilized them for the synthesis of DCPs and related conjugates. Oxygenated dibenzo-alpha-pyrones (DBPs), on being synthesized in the animal living systems from EPA, are transformed into several DBP-conjugates (HPLC-tR: 2.31, 2.99, 3.46 and 3.86 min). These components were also detected in DCPs, isolated from shilajit. A dynamic turnover of these constituents was observed (FIGURE 2) on oral administration of DCPs (200 mg/Kg b.w.) to albino rats, followed by HPLC analysis of the constituents in the corresponding RBC. From this and other observations, it is increasingly apparent that DCPs, which are also the constituents of animal tissues, act in the form of enzymes and hormones in regulating and fulfilling several biological functions.
DCPs may participate in a variety of functions in the producer organisms including protective-colorations which provide protection from radiation, electron transport, and enzyme activity and in their sustenance and development. DCPs, which have transport properties like those of the fulvic acids (FAs) of shilajit, can enter into recipient cells and elicit biological responses much more pronounced than free DBPs. Extensive pharmacological and immunological evaluations of DCPs have now demonstrated them to be 2-5 times more potent than any of the other constituents of shilajit as adaptogen and immunomodulator.
The systemic transformation of 3-hydroxy- and 3,8-dihydroxydibenzo-alpha pyrone (DBPs) into arginine and glycine phospholipid conjugates, their resultant metabolism, and the systemic assimilation/turnover of DCPs, when fed to rats through oral route, suggest the role of these compounds in energy storage in living systems.
Arginine phosphate plays an important role in the storage of energy in invertebrates;
the same role is played by creatine produced from a combination of argininephosphate and glycine phosphate in vertebrates. Creatine phosphate and arginine phosphate are reserves of phosphates of high energetic potential and, hence, the name 'phosphagens' given to these compounds as shown in Scheme 1.
ATP
(Synthesis catalysed by shilajit) ADP
Creatine/Arginine Phosphagens (in shilajit-DCPs) Scheme 1 An energetic coupling represents the energy storage reaction when ATP is present in excess and, inversely, the formation of ATP by the reverse reaction when the cells need the ATP. Should we consider the biosynthesis and balance of DBP-phosphagen complexes in living organisms as the indices of their energy status, then in the event of dearth of these phosphagens, administration (p. o.) of shilajit would replenish them.
The chromoproteins (DCPs), participate in a wide variety of functions in animal biological systems. DCPs have been encountered in the lowest form of animal 1 S organisms (foraminifera, in other marine invertebrates, and in haemolymph of termites), in higher animals (rodents, beaver, chimpanzee, sheep), and in man.
DCPs participate in electron transport [systemic ATP synthesis by DCPs is conceivable because oral administration of DBP produced creatine and conjugated product(s)] and oxido-reductase reactions; catalyze other enzyme activities (e.g., ATPase function as described in Cheesman, 1967); the larger abundance of DCPs in female invertebrate fossils of the Jurassic (e. g., Idiocyclocerus and Kamptokephalites spp.) (Table 2) compared to their male counterparts, found in the present study, suggests their role in the development and protection of the embryos. The superior (qualitative and quantitative) biological functions of the DCPs compared to those of EPA, DHA, and free DBPs formed from EPA/DHA are described in the sequel.
Thus, features of the isolation and use of DCPs are as follows:
1. Stabilization of protein and the colored molecules, carotenoids (e.g., astaxanthin and derivatives) and indigoids (e.g.,indigotin and indirubin) against different forms of stress and onslaughts.
2. Protective coloration, - the use of color as a means of concealment from prey-predator functions; utilization of the potently antioxidant pigments from deleterious effects of radiation; e.g., photo-oxidation of lipids, and from oxidative free radicals.
5 3. Development of the producer organisms. The large number of pigmented proteins which have been found in the ovaries of invertebrates and the higher abundance of these compounds in the female species compared to those of the male counterparts, suggest their function in the species development.
Lipoprotein complexes which have been noted in the blood/haemolymph of many invertebrates 10 may be involved in the transport of the carotenoids and other pigment molecules; the linkage to a protein making the fat-soluble pigments water-soluble. Hence the chromo-molecules in DCPs were found associated with both the lipid as well as the protein fractions of the complex molecules.
4. Development of embryos in invertebrates require carotenoproteins.
15 5. As simulator/surrogates of bio-energetics, e.g., ATP; creatine synthesis.
6. Immuno-modulator.
7. Captivators of oxidative free radicals, Reactive Oxygen Species (ROS), Reactive Nitrogen Species (RNS).
20 8. Scavengers/chelators of loose metal ions (Fe, Cu, Mn, W).
9. DCPs play a crucial vitalizer role in all organisms since the evolution of life on Earth.
The features of the isolation and use of DCPs provides a skin care, hair care, pharmaceutical, or nutritional formulation comprising a DCP composition present in an amount of about 0.05% to about 50% by weight. Also, the skin care or protection formulation can be in the form of a lotion, cream, gel or spray, wherein the DCP
composition is present in an amount of about 0.05% to about 5% by weight.
The features of the invention provide a pharmaceutical formulation comprising a DCP composition wherein the pharmaceutical formulation is in the form of a tablet, syrup, elixir or capsule.
The features of the invention provides a nutritional formulation comprising a DCP composition wherein the nutritional formulation contains about 0.5% to about 30% of the DCP composition by weight.
The features of the invention provides a veterinary formulation comprising a DCP composition wherein the veterinary formulation contains about 0.5% to about 30% of the DCP composition by weight.
The features of the invention provides a process for isolating DCP
S compositions from shilajit compositions comprising about 0.5% to about 10%
w/w dibenzo-alpha- pyronechromoproteins, the process includes the steps of 1)extracting shilajit successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration; 2) triturating the ethyl acetate and methanol insoluble material with hot water and then citrate buffer of pH 5.0; 3) filtering the combined extract-mixture to remove insoluble substances comprising polymeric humic materials, minerals and metal ion salts; 4) gradually saturating the combined aqueous filtrate with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating the combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering the DCPs and evaporating the filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from shilajit.
The features of the invention provides similar processes for extracting and isolating DCPs from fossils of ammonites, fossils of corals, and from invertebrates.
The features provide a method for treating chronic stress disorders, including administering to a patient in need thereof a therapeutically effective amount of a DCP
composition and a method for increasing cognition learning which includes administering a DCP composition.
The following examples will serve to further typify the nature of the invention.
Extraction and isolation of DCPs of shilajit Shilajit (rock powder) was extracted successively with hot ethyl acetate and methanol to remove free organic compounds which were subsequently analyzed comprehensively (Tables 3-6). The marc (ethyl acetate- and methanol-insoluble material) was triturated with hot water and citrate buffer (pH S.0) and then filtered.
The marc was analysed for inorganic minerals and humic substances. The aqueous solution was differently saturated with ammonium sulfate (25%, 50%, 75%
and 100%) when DCPs of different complexities were precipitated as purple-brown solid. The solid residues were subjected to Sephadex gel filtration and electrophoresis for further purification of DCPs. The same general procedure was followed for the isolation of DCPs from the marine samples. In the precipitation of DCPs from aqueous solutions, however, one variation constituted addition of acetone, instead of ammonium sulfate and to isolate DCPs from acetone-insoluble and soluble fractions in the usual way.
Extraction and isolation of DCPs of marine invertebrate fossils (general procedure) In a typical experiment, fossils of Nummulites (foraminifera, GSI type No. 10772) were dried, finely powdered and then extracted with hot ethyl acetate to remove low Mw organic compounds (free oxygenated dibenzo-alpha-pyrones, hydroxyacetophenones, aromatic acids etc., cf. Tables 3-6) as the ethyl acetate-soluble fraction. The mart (insoluble in ethyl acetate) was further extracted with O.1N HCI.
The aqueous acidic extract was evaporated. The residue was dissolved in minimum volume of distilled water. The aqueous solution was divided into two parts.
One part was differently saturated with ammonium sulfate and to the other part, acetone was gradually added. Addition of both ammonium sulfate and acetone precipitated mixtures of oxygenated dibenzo-alpha-pyrone chromoproteins (DCPs) as light brown solid. The acetone-soluble fraction, on evaporation also afforded a further crop of DCPs of lesser complexities. These compounds were subsequently subjected to chromatographic (HPLC) and spectroscopic (IR, 1H-NMR) analyses to establish their general identities with DCPs.
Extraction of living marine invertebrates (general procedure) Living marine invertebrates mainly molluscs (Telescopium, Cerethedia etc.) were collected from coastal region of Bay of Bengal and brought to the laboratory as live specimen. Each specimen was sacrificed and body flesh was taken out from shell. Body flesh was then extracted with hot ethylacetate to remove low molecular weight organic compounds and lipids. The mart (EtOAc insoluble portion) was further extracted with Bligh & Dyer solvent system [CHC13: MeOH (1:2) as initial solvent; CHC13: MeOH: H20 (1:2:0.8) as intermediate solvent and CHCl3: MeOH
(1:2) as final solvent]. The Bligh & Dyer (B&D) solvent was evaporated under reduced pressure. The B&D extractive was dissolved in minimum volume of distilled water. The aqueous solution was divided into two portions. One portion was gradually saturated with ammonium sulphate and to the other portion, acetone was gradually added. Addition of both ammonium sulphate and acetone precipitated mixtures of DCPs (oxygenated dibenzo-alpha-pyrone chromoproteins) as off white solid. These compounds were analyzed by different chromatographic (HPLC) and spectroscopic (IR, 1H-NMR,GC-MS) techniques to establish their identities with shilajit DCPs.
Separation and Partial Characterization of DCPs (I and II) Sodium dodecyl sulfate polyacrylamide gel electrophoresis was carried out by the method of Weber and Osborn (1969) with 10% acrylamide in presence of 0.1%
(w/v) SDS. The sample was preheated at 100° C for 3 minutes in presence of 2-mercaptoethanol and 3% SDS. Tris-glycine buffer containing 0.1% SDS (pH 8.4) was used as running buffer. Bromophenol blue was used as tracking dye.
Electrophoresis was performed at a constant current of 120V, 40 mA for 90 min.
A
pinkish-orange band appeared towards the top (DCP-n followed by bromophenol blue and then a yellow band (DCP-II). After the run was over, these three bands were cut with a fine blade and homogenized, separately, in 1.5 ml distilled water in a mortar-pestle. Each homogenate was decanted into a micro-centrifuge tube and centrifuged at 7000 rpm for 10 minutes. Each supernatant was divided into two parts and evaporated under vacuum. One part of the sample (ca. 50 pg) was dissolved in HPLC
running solvent (water:acetonitrile:orthophosphoric acid = 67:32:1) and analysed by HPLC. The other part was subjected to lipase reaction (see EXAMPLE 5).
The DCP-I compound was obtained as a pink colored powder; pH (1%
aqueous solution) 8.02; N, 17.8%; metal ions (in ppm) Fe, 186.3; Cu, 8.8; Zn, 23.4.
The DCP-II compound was obtained as a light brown powder, pH ( 1 aqueous solution) 7.8; N, 16.4%; metal ions (in ppm) Fe, 262.4; Zn, 48.7.
Further purification of the two chromoproteins was carried out by Sephadex ion exchange on DEAE-Sephadex G-50, using phosphate buffer (pH 7.2). Gel electrophoresis (10% SDS, thickness 1.5 cm; constant current 20 mA, tris-glycine buffer, pH 8.3) showed two major bands in each of DCP-I, 2-S KD and DCP-II, 10-KD; with several lighter bands at higher Mw ranges.
Both DCP-I and DCP-II exhibited HPLC and spectroscopic (IR, 1H-NMR) characteristics typical of DBP-carotenoproteins.
Lipase reaction of DCPs The sample (ca.50 wg) was dissolved in 0.5 ml 1M tris-buffer of pH 8Ø100 g1 (2.2%) CaC12.2H20 and 250 ~,1 (1%) bile salts were added to each sample.
Working solution of lipase (Hog pancreatic lipase, Sigma, 1 mg in 2 ml tris-buffer) was then added to each sample. The mixtures were agitated by magnetic stirrer for three hours at 37° C. After the incubation period, 1 ml ethanol and 1 ml 6N HCl was added to the mixtures to stop the reaction. The hydrolyzed products were extracted by diethyl ether and dried over anhydrous sodium sulfate. The remaining portions were evaporated on water bath in porcelain basin. The residues were dissolved in minimum volume of HPLC solvent (water:acetonitrile:orthophosphoric acid =
67:32:1) and 20 w1 was injected into HPLC for analysis. Collective ether extractives, after lipase hydrolysis, was also analysed in HPLC in the same solvent system to characterize the nature of lipoidal compounds.
In the HPLC chromatograms of DCPs, precipitated from aqueous solution of shilajit by differently saturating with ammonium sulfate, a large number of peaks appeared in the 75 and 100 percent-saturated fractions (Fig. 3). This observation suggested that shilajit DCPs are replete with relatively low Mw lipoproteins (like chylomicrons/lipocalins). However, tR 1.5 min signal (Fig. 3) suggested that higher Mw proteins, like B-48, might also occur in DCPs. The presence of adherent ligands, particularly DBPs, was also suggested.
Another observation was the association of DBPs as ligands in DCPs (Fig. 4).
In this figure, PR-25, -50, -75 and -100 denote respective ammonium sulfate precipitated protein fractions. Note that in the PR-50 and -75, the abundances of 3,8 dihydroxydibenzo-alpha-pyrone are very high suggesting that the DBPs are preferentially associated with low/medium MW lipoproteins.
Determination of amino acids The mixture of amino acids produced in the acidic hydrolysates of DCPs was converted into trimethylsilyl derivatives (O-/N-TMS) and then subjected to GC-MS
analysis by using corresponding markers, similarly prepared with the standard amino acids.
Determination of creatine 5 This method, based on the color reaction developed by creatine in the presence of diacetyl and a-napthol, was described by Barrett (1936). Briefly, to a neutral solution of the test sample, containing not more than 60 ~g of creatine, 2 ml of 1% a-napthol in alkali was added followed by 1 ml of diacetyl ( 1 % solution diluted to 1:20 before use). The solution was shaken, and the color was measured after 30 min at 525 10 m~.
Determination of arginine Arginine, isolated from DCPs by selective degradation (lipase), was decomposed by arginase (5 to 10 units/ml) to ornithine and urea and were assayed 15 colorimetrically (using acid mixture, - 1 vol. H2S04; 3 vol. syrupy H3P04;
1 vol. H20;
urea standard, 50 ~,g/ml in H20; and a-isonitrosopropiophenone, 4 g. in 100 ml of 95% ethyl alcohol).
Comparative study of the effects of shilajit constituents on chronic stress 20 A comparative study of shilajit bioactive constituents from EPA, DHA, DBPs and DCPs, was carned out to determine their adaptogenic potency against chronic stress (CS) in albino rats. It is now increasingly becoming evident that CS of a mild but unpredictable nature which the animal is unable to cope with (inescapable stress), is clinically more relevant than acute stress even when the latter is severe in nature. It 25 is believed that chronic, unpredictable, and inescapable stress resembles the situation faced by an individual that ultimately results in chronic stress- induced physiological perturbation and disease.
Animals The investigation was carried out on CF strain albino rats, of either sex (140-180g), housed in colony cages at an ambient temperature of 25 t 2° C, with a 12h. light /12h. dark cycle. Experiments were conducted between 0900 and hrs.
EPA, Eicosapentaenoic acid DHA, Docosahexaenoic acid DBPs, 1:1 mixture of 3- hydroxy - and 3,8 -dihydroxydibenzo-alpha-pyrone DCPs, DBP-chromoproteins Induction of chronic stress The procedure of Armario et al (1993) was followed. Briefly, rats were randomly assigned to control or stress groups. Those assigned to the stress groups were subjected to 1h foot shock, through a grid floor, every day for 14 days.
The duration of each shock (2mA) and the intervals between the shocks were randomly programmed between 3-5 sec. and 10-110 sec., respectively, to make the stress unpredictable. The shock chamber had high walls which made escape from shock impossible.
Test compounds and Vehicles EPA (Aldrich, Milw.), DHA (Sigma), DBPs and DCPs were separately suspended/ dissolved in 0.3% carboxymethylcellulose(CMC) in distilled water and administered orally (p.o.) , for 14 days , starting on day 1, 60 min prior to electroshock. Control animals received only the vehicle in either unstressed or the stressed rats for the same period in a volume of 2.Sm1/kg, p.o. Estimations were conducted on day 14, one hour after the last stress procedure and two hours after the last test compound or vehicle was administered.
Determination of intensity of chronic stress effects Gastric ulcerations (Bhattacharya et a1.,1987). On day 14, rats were killed by decapitation the stomach was split open along the greater curvature and the numbers of discrete ulcers were noted. The severity of ulcers was scored, after histological confirmation, as 0 = no ulcers; 1 = changed limited to superficial layers of mucosal with no congestion; 2 = half the mucosal thickness shows necrotic changes; and 4 =
complete destruction of mucosa with hemorrhage. Thereafter, the pooled ulcer score was calculated according to the method of Bhattacharya et al. (1987).
Adrenocorticoid activity Adrenal gland ascorbic acid (Zenker and Bernstein, 1958) and corticosterone concentrations (Selye, 1936), and plasma corticosterone levels (Selye, 1936) were determined to substantiate the validity and intensity of the stress procedure adopted.
Results and discussion Chronic stress (CS) significantly increased the incidence, number and severity of gastric ulcers. All the four test compounds had, albeit in different degrees, dose-related anti- ulcerogenic effect. The extent of the anti-ulcerogenic effect was in the S order: DCPs>DBPs>DHA~EPA as follows in Table-7.
Table-7: Effects of shilajit constituents on chronic stress (CS) induced gastric ulceration in albino rats.
Treatment groups n Ulcer o No. of ulcersSeverity of ulcers (mg/kg, . o. incidence /o Chronic stress (CS) 12 100 19.8 ~ 3.0 32.4 ~ 5.1 EPA~S~ + CS 10 70 16.5 t 3.4 28.3 ~ 7.7 EPA ~,o~+ CS 10 60 14.3 t 4.4 26.4 ~ 6.2 DHA ~5~ + CS 10 70 15.8 ~ 4.0 28.1 ~ 5.9 DHA ~~o~ + CS 10 60 14.7 t 3.8 25.0 ~ 5.2 DBPs ~5~ + CS 10 SOa 11.7 ~ b 3. 13.2 t 3.0b la DBPs ~lp~ + CS 10 40a 8.2 ~ 2.2b 9.7 ~ 2.0b DCPs ~5~ + CS 10 30a 9.0 ~ 2.8b 12.1 ~ 2.36 DCPs ~lp~ + CS 10 20a 7.3 ~ 1.86 8.1 ~ 2.06 ° p < 0. 05 vs CS group ( chi square test); b p < 0. 05 vs CS group.
Chronic stress (CS) caused marked depletion of adrenal gland ascorbic acid and corticosterone concentrations with concomitant increase in plasma corticosterone levels. These findings also suggest that the stress protocol used in this study induced pronounced stress. As expected, all the four test compounds (EPA, DHA, DBPs, DCPs) reversed, to different extents, these stress- induced adverse effects in a dose related manner; their stress- attenuating actions, in doses used, had no per se effect on the indices of stress investigated as follows in Table 8.
Table-8. Effects of Shilajit constituents on chronic stress (CS) induced alteration of adrenal gland ascorbic acid and corticosterone concentrations and plasma corticosterone level Groups Adrenal ascorbicAdrenal Plasma m k . o. n acid 100m corticosteronecorticosterone ( ~ g> P ) (~t~ g) (w1~100mg) (p~dL) Vehicle 8 300.2 t 38.4 4.4 + 0.7 14.0 + 1.3 EPA ~5~ 6 308.8 t 28.7 5.7 + 1.4 15.0 + 0.6 EPA~IO~ 6 310.5+26.0 5.20.8 15.5+1.1 DHA ~5~ 6 309.4 + 30.4 4.8 ~ 1.2 15.0 t 0.9 DHA ~lo~ 6 308.9 + 27.4 5.5 ~ 1.0 14.7 ~ 1.0 DBPs ~5~ 6 309.1 ~ 25.8 5.0 t 1.3 15.7 + 1.4 DBPs ~lo~ 6 315.5 + 25.5 5.4 t 1.7 14.9 + 1.5 DCPs ~5~ 6 308.5 + 25.5 4.9 + 0.8 14.7 + 1.0 DCPs ~,o~ 6 312.5 t 26.0 5.1 t 1.5 15.3 t 1.5 Chronic stress 12 114.7 + 16.0a 1.7 + 0.5a 28.0 + 3.0a (CS) EPA~S~+CS 6 138.5+18.2 2.3+0.8 22.1+2.9 EPA ~io~ + CS 6 144.2 + 14.7b 2.9 + 0.7b 18.3 ~ 1.86 DHA ~5~ + CS 6 140.7 t 20.5 2.5 + 1.0 22.5 ~ 3.5 DHA ~lo~ + CS 6 148.0 t 16.7b 2.8 + 1.0b 17.9 + 0.9b ' DBPs ~5~ + CS 6 173.4 + 18.2b 3.0 + 1.4b 17.3 + 0.76 DBPs ~lo~ + 6 198.5 + 20.76 3.2 ~ 1.1b 16.8 ~ 1.06 CS
DCPs ~5~ + CS 6 200.3 ~ 25.2b 3.5 + 1.06 14.7 ~ 1.16 DCPs ~,o~ + 6 242.2 + 27.36 3.9 + 0.86 14.0 ~ 1.8b CS
a p < 0. OS vs vehicle- control group; b p < 0. OS vs CS group The effects of DBPs and DCPs on chronic stress induced suppression of humoral immunity in rats (Table-9) and in rat brain frontal cortex SOD, CAT, GPx and LPO activities (Table-10) established the major bioactivity-contribution of DCPs to shilajit.
Table-9: Effects of DBPs (1:1 mixture of 3-OH and 3,8-(OH)z dibenzo-alpha-pyrones) and DCPs on CS -induced perturbations in rat brain frontal cortex SOD, CAT, GPx and LPO activitiesa.
Treatment SOD (pg/mg CAT (~,g/mg GPX (pg/mg LPO (n mol protein) protein) protein) ~ B ej S/gm (mg/Kg, p.
o. ) Vehicle 16.81.4 20.21.9 0.080.02 3.320.6 Chronic stress30.91.66 9.60.8b 0.02O.OIb 7. 40.96 CS
DBPs (5) 22.00.9 12.80.6~ 0.030.009 5.460.7~
+ CS
DBPs (10) + 20.40.8' 14.60.8 0.050.008 4.320.8 CS
DCPs (1.0) + 40.9~ 15.41.2 0.050.06 4.420.09 CS .
DCPs (2.0) + 41.1 17.80.9 0.07O1 1.220.08 CS .
a = Data are means ~ SEM; n= 8 to 10 replicates.
b = p < 0.05 vs vehicle control group.
= p < 0.05 vs chronic stress group (CS).
SOD, superoxide dismutase, CAT, catalase.
GPx, glutathione peroxidase.
LPO, lipid peroxidation Test drugs were administered 14 days concomitant with stress procedure.
Table-10: Effects of DBPS and DCPs on chronic stress-induced suppression of humoral immunity in ratsa.
Treatment groupsDetectable level of haemagglutination titre to SRBC
(mg/Kg, p. o. 1 /2 -1/16 1/32 - 1/128 1/256 -1/512 ) Vehicle - 74 26 Chronic stress 62b 38b -DBPs(S) + CS 48 52 -DBPs (10) +C5 32 68 -DCPs (1.0) +CS 26 62 -DCPs (2.0) +CS 22 72 -result are expressed in %; n = 8 to 10 replicate;
b = p < 0.05 vs vehicle-treated control group.
5 ° = p < 0.05 vs chronic stress group (CS).
(Chi-square test). Animals were bled on day 14 after sensitization with SRBC
on day 1.
Effect of DCPs on Arachidonic Acid Metabolism 10 The anti-inflammatory effects of shilajit and its major bioactive constituents, DCPs, were evaluated by using arachidonic acid (AA) metabolism. The effect of shilajit on AA metabolism was tested in isolated human neutrophils. Shilajit and DCPs both inhibited the biosynthesis of AA-lipoxygenase pathway products, namely, leukotriene-B4 (LTB4), 5-hydroxyeicosatetraenoic acid (5-HETE), 12-15 hydroxyeicosatetraenoic acid (12-HETE) and also inhibited the biosynthesis of the cycloxygenase product, 12-hydroxyheptadecatrienoic acid (12-HHT), in a dose dependant manner. Maximum inhibitory effects were observed at a concentration of 50 ~,g/ml of shilajit, while in case of DCPs, it was only 10 ~g/ml. A 1:4 combination of 3,8-dihydroxydibenzo-alpha-pyrone (DBP) and fusoms exhibited similar equi-20 active effect at a concentration of 20 ~g/ml. Fusoms of shilajit are used as an efficient systemic drug delivery agent (Ghosal, 2003). These findings suggest that the inhibition of synthesis of leukotrienes (and equivalents) by shilajit and its major bioactives (DCPs) is responsible for their therapeutic action, e.g.,in the treatment of bronchial asthma.
The results as shown in Tables 7 and 8 suggest that DBPs (1:1 mixture of 3-hydroxy - and 3,8 -dihydroxydibenzo-alpha-pyrone) are biologically more active than either of its precursors, namely, EPA (eicosapentaenoic acid) or DHA
(docosahexaenoic acid) while DCPs are the most active among the bioactive agents of S shilajit. Similar graded effects of DBPs and DCPs were observed on chronic stress (CS)-induced perturbations in rat brain antioxidant enzymes and LPO activities (Table-9) and CS-induced suppression of humoral immunity in rats (Table-10).
The Significance of DCPs in living system and the fate of DCPs after oral administration to experimental animals are also shown.
Antioxidative Actions of DCPs Inhibition of Fe-ADP-ascorbate induced lipid peroxidation (LPO) in rat brain by DBP and DCPs Albino rats (Sprague Dawley strain) were sacrificed by cervical dislocation 1 S and decapitation. Brains were dissected out and 10% w/v homogenate was prepared in 0.15 M KCI. The brain homogenate was centrifuged at 1500 rpm for 10 minutes and the supernatant was used for the study. The incubation mixture contained in a final volume of 1 ml., brain homogenate (500 p1), distilled water (100 w1) or test . compounds dissolved in solvents at different concentrations (10 to 100 pg/ml of the final volume). Peroxidation was initiated by adding FeCl3 (100 pM), ADP (1 mM) and ascorbate (100 ~M) to give the final concentration stated. After incubating at 37° C for 30 minutes, the reaction was stopped by adding acetic acid buffer (1.5 ml, pH 3.5) and thiobarbituric acid solution (1.5 ml, pH 7.4) to 1 ml of LPO
mixture. The reaction mixture was heated at 85° C for 30 minutes, cooled, centrifuged (2000 rpm for 10 minutes) and the absorbance of the supernatant was measured at 532 nm.
ICso values were calculated in the usual way by plotting the concentration of the test compounds versus percent inhibition of LPO.
Metal-ion Chelating and Scavenging Actions of DCPs This was determined by the stability of metal-ion complexes/conjugates of DCPs and their capacity to scavenging/chelating loose metal ions.
The ion-exchange equilibrium method of Schnitzer and Skinner (1966) was used for the abovementioned determination. Briefly, amounts of DCPs ranging from 10 to 50 mg were weighed into 50 ml volumetric flasks and dissolved in approximately 40 ml of distilled water. To each flask, 5 ml of 1N-KCl solution was added. One-gram quantities of K-saturated Dowex-50 resin (20-SO mesh, Bio-RAD
Laboratories) were weighed into 125 ml of ground glass-stoppered Erlenmeyer flasks.
The solution containing the natural DCP-metal ion conjugates (Fe, Cu, Zn), admixed with KCI, were transferred to these flasks and shaken at 241° C for 1 hour. In a separate experiment, known amounts (approx. 500 p,g) of aqueous solutions of MnCl2, MoCl3 and WC14 were added separately, to aqueous solutions of the DCP-KCI. The mixtures were shaken as before and the stability constants were determined as follows. The exchange resin was then removed by filtration. The filtrates and washings, containing metal ions, Fe2+, Cu2+, Zn2+, and those of the added metal ions, were analyzed by Atomic Absorption Spectroscopy (Techtron AA-3 Atomic Absorption Spectrophotometer).
At pH 3.5, log stability constants for the different DCP-metal ion complexes 1 S were: DCP-Cu, 3.44; DCP-Fe, 2.83; DCP-Zn, 1.47. The order of stability of the different metal ions was (expressed in the decreasing order): Cu2+>
Fe2+>Mn3+>Znz+>Mo3+>W4+.
The results as shown in Tables 7 and 8 suggest that DBPs (1:1 mixture of 3 hydroxy - and 3,8 -dihydroxydibenzo-alpha-pyrone) are biologically more active than either of its precursors, namely, EPA (eicosapentaenoic acid) or DHA
(docosahexaenoic acid) while DCPs are the most active among the bioactive agents of shilajit. Similar graded effects of DBPs and DCPs were observed on chronic stress (CS)-induced perturbations in rat brain antioxidant enzymes and LPO activities (Table-9) and CS-induced suppression of humoral immunity in rats (Table-10).
Stress begets oxidative stress. The antioxidant actions of DCPs are pronounced as shown in Tables 11 and 12 which shows the significance of DCPs in living systems and the fate of DCPs after oral administration in experimental animals.
Table 11. Effect of DBP and DCPs on LPO
*AcMe pptd. Note the significant antioxidant effect of DCPs Table-12. Antioxidant activity of DCPs.
ROS Captodative RNS Captodative Activity Activity .
(ICso) (ECSO) In terms of In terms of protein protein content of DCPs content of DCPs Total DCPs Total DCPs (g0o~o protein (600~o protein in in DCPs DCPs) l5mcg/ml 9 ~g/ml 80.80 ~g/ml 48.48 ~g/ml Note: In terms of ~M of amounts, the antioxidant activities of DCPs are highly significant.
Personal Care / Cosmetic Formulations A. SKIN REJUVENATING (0/W) LOTION
Ingredients % w/w Phase A
Polyglyceryl-3 Methyl Glucose 3.50 Distearate Glyceryl Stearate, PEG-100 Stearate2.50 Dicapryl ether 5.00 Coco-Caprylate/Caprate 5.00 Propylene Glycol Dicaprylate/Dicaprate3.00 Almond Oil ~ 2.00 Cetyl alcohol 1.50 DCPs (present invention) 2.00 Phase B
Glycerin 3.00 Propylene glycol 3.00 Allantoin 0.20 Methylparaben 0.15 Water, deionized q.s.
Phase C
Phenoxyethanol and Isopropylparaben0.50 and Isobutylparaben and Butylparaben Total 100.00 Procedure Combine A, stir and heat to 65° C. Combine B, stir and heat to 65 ° C. Add A
to B while stirnng. Homogenize at moderate speeds to avoid foaming, while allowing mixture temperature to cool to 40° C. Add C, homogenize. Stir gently until mixture is homogenous.
B. SUNSCREEN O/W LOTION (SPF 15) Ingredients % w/w Phase A
Propylene Glycol Isoceteth-3 5.00 Acetate Octyl methoxycinnamate 7.50 Benzophenone-3 3.00 Homomenthyl Salicylate 7.00 Steareth-2 0.40 Steareth-10 0.80 Acrylates/C. sub. 10-30 Alkyl 0.18 Acrylate Crosspolymer Synthetic Wax 0.80 Dimethicone 1.00 DCPs (present invention) 1.00 Phase B
Demineralized water q.s.
Phase C
Demineralized water 19.82 Phenylbenzimdazole sulfonic acid1.00 Propylene glycol 2.00 Triethanolamine 0.90 Propylene Glycol and DMDM Hydantoin1.00 and Methylparaben Total 100.00 Procedure Combine A, stir and heat to 80° C. Heat B to 80° C. Add A to B
while stirnng 5 with a propeller mixer. Continue stirnng A/B for 20 minutes while maintaining the temperature between 70-75° C. Combine C, heat and stir to 45° C
until dissolved.
Add C to A/B with agitation. Qs water. Gently homogenize A/B/C allowing mixture to cool to room temperature. Adjust pH to ~6.5, if necessary, with TEA. Use high shear spray device to dispense.
C. LIQ UID FOUNDATION
A liquid foundation having the following formulation was prepared according to the following method.
S. No. Ingredients % w/w 1 Lanolin 7.00 2 Liquid Paraffin 5.00 3 Stearic Acid 2.00 4 Cetanol 1.00 Glycerin 5.00 6 Triethanolamine 1.00 7 Carboxy Methyl Cellulose0.70 8 Deminaralized Water q.s.
9 Mica 15.00 Talc 6.00 11 Titanium Oxide 3.00 12 Coloring Pigment 6.00 13 DCPs (present invention)0.50 14 Ultraviolet Screening q.s.
Agent Perfume q.s.
5 Procedure A. The components (1) to (4) were mixed and dissolved together.
B. The components (9) to ( 12) were added to and uniformly admixed with the foregoing mixture A.
C. The components (5) to (8) were uniformly dissolved together and the resulting 10 mixture was maintained at 70° C.
D. The foregoing mixture C was added to and uniformly admixed with the foregoing mixture B to give an emulsion.
E. After cooling the foregoing mixture D, the components (13) to (15) were added thereto to give a liquid foundation.
Ammonium Arachidonic C-14 to C-20 C- to C-sulphate EPA+DHA 16:0+18:0 acid 18a 246 precipitation 25% 14.94% 4.44% 0.94% 17.95% 82.05%
50% 20.95% 10.61% 0.92% 18.17% 81.83%
7$% 0.60% 9.22% 27.28% 48.05% 51.95%
100% 0.14% 4.26% 1.28% 43.30% 56.70%
a+b = 100% of total fatty acids.
~ = Expressed as % of total fatty acids present in each sample.
Many of the shilajit-bearing mountains have been found to be rich storehouses of marine invertebrate fossils, such as of the phyla of Arthropoda, Brachiopoda and Mollusca, of the Phanerozoic era. This co-occurrence of shilajit and the invertebrate fossils, as depicted in Table 2, is a consistent phenomenon.
Table 2. Marine invertebrate (fossils and living) analyzed for DBPs and DCPs.
Age of specimen Phylum/Class: Genus, species(period) Sr Place of Occurrence No . (Order/Family) Reference/Type numbera~b Fossils Arthro oda/Trilobita:
Cambrian GSI
-I Ptychoparia spitiensis a II Asaphus s . Ordovician Brachio oda/Articulata III Kutchithyris acutiplicataJurassic GSI-6596aKutch, Gujarat Consinanthris sp. Cretaceous Trichy ,Tamil Nadu (Terebratellacea) Mollusca/Cephalo oda V Nautilus angustus Cretaceous ~ aloor TN
y ' (Ammonoidea) GSI-97425a VI Perisphinctes aberrance Jurassic Kutch GJ
(Ammonoidea) GSI-2043a VII Kamptokephalites dimerus Jurassic Kutch GJ
(Ammonoidea), female sp. JUM - 1314b Jurassic VIII K. dimerus, male sp. b Kutch, GJ
Idiocyclocerus perisphinctoidesJurassic Kutch GJ
(Ammonoidea), female sp. JUM-332b Jurassic X I. perisphinctoides, maleb Kutch, GJ
sp. JUM-323 XI Paryphocerus sp. Jurassic Muktinath, Nepal (Ammonoidea Foraminifera (Protozoa XII Alveolina sp. Cretaceous Kutch, Gj XIII Discocyclina sp. Paleocene, Javana, Trichi Oligocene XIV Nummulites sp. Early Miocene Kutch, Gj, Jayanthia Hill, India XV Nacutus sp. - Kutch, Gj Cnidaria/Anthozoa (coral) XVI Diploria - Bay of Bengal Cnidaria/Hydrozoa (coral) XVII Stylaster - Bay of Bengal Table 2 Continued. Marine invertebrates (living) Ph lum/Class:Age of specimen Place of Parts Sr. species (period),Reference/Type No Genus , numbera~b Occurrence examined (Order/Family) Living invertebrates - MolluscalGastropoda Coastal Telescopium region of Body X~ telescopium - Bay of flesh Bengal Coastal Cerethedia region of Body cingulata _ Bay of flesh Bengal Mollusca/Cephalopoda Coastal region of Body XXI Loligo sp. _ Bay of flesh Bengal Arthropoda/Crustacea Coastal Osipoda region of Body XXII macrocera _ Bay of flesh (Red crab) Bengal Coastal region of Body XXIII Copepoda _ Bay of flesh Bengal a Geological Survey of India, Calcutta b Geological Sciences Museum, Jadavpur University, Calcutta (through the courtesy of Prof. S. Bardhan) The remaining samples were obtained from Messrs Hindusthan Minerals, Calcutta.
Also, the organic compounds found in these fossils and in shilajit are very similar as shown in Tables 3-6.
Table-3. HPTLC data of compounds found common in marine invertebrates and shilajit Compound Developing RF Reflectance max. Mode of Solvent /nm detection 3-Hydroxy-DBP A 0.51 222, 230, 278, 300,D-Q/M-F
DBP~acyl-3,8-dihydroxy-A 0.35 218, 252, 304, 330,D-Q/M-F
3,8-Dihydroxy-DBP A 0.22 215, 236, 272, 294,D-Q/M-F
Dimeric-DBP B 0.25 215, 280, 332, 348 D-Q
Glucitol B 0.20 - T, BMP
Ribitol B 0.18 - T, BMP
Allantoin C 0.42 228, 262 D-Q
Uric acid C 0.33 222, 288 D-Q
Proline C 0.25 - T, Nin.
Hydroxyproline C 0.20 - T, Nin.
Glycine C 0.16 - T, Nin.
a the acyl moiety was constituted of C 16-C20 fatty acids Q quenching mode D deuterium lamp, wave length 260 nm M mercury lamp, wave length 360 nm; F, fluorescence mode T tungsten lamp, wave length 520 nm;
BMP, benzidine-metaperiodate staining reagent for polyols, sugars;
Nin, ninhydrin reagent for detection of amino acids Table-4. HPLC data of compounds found common in marine invertebrates and shilajit Compound Retention time PDA ~,max nm tR in min 3, 8-Dih drox -DBP 5.55 238, 295, 318, 337, dimer 375 2, 4, 6 6.22 222, 268, 318, 342 Trih drox aceto henone 2, 4- 6.41 220, 230sh, 263, 275, Dih drox acetophenome 325 3, 5- 6.50 218, 263, 315 Dih drox aceto henone Benzoic acid 8.197 228, 272 3, 8-Dih drox -DBP 10.08 238, 271, 280, 300, 3, 8-DBP- uinone 11.33 220, 230, 290, 345, Monoacyl-3, 8-dihydroxy-25.68 243, 290, 304, 342 DBPsa 3-Hydroxy-DBP 31.06 233, 271, 295, 304, C16-C20 fatty acids were detected after hydrolysis followed by GC of their methyl esters using markers Table - 5. GC-MS data of compounds found common in marine invertebrates and shilajit Compound Mol. formulaRetention time,MS : m/z tR in min Dotriacontanol C32H60O 11.032 466 M+
o - CgH1002 12.110 150(M+), 135, 107, Methox acetophenone EPA as methyl esterC21H3202 19.033 no detectable M+, fragment-ions:287, 284, 279, 274, 262, 201, 187, 105, Dotriacontane C32H66 19.048 450(M+
Oleoyl alcohol C18H360 22.751 268(M+) Hentetracontanol C41Hg40 22.899 592 M+
DHA as methyl esterC23H3402 23.150 no detectable M+, fragment- ions:
268, 262, 254, 247, 223, 219, 105, 91 Methyl-4- C1gH380 23.416 380(M+) h drox octadecanoate Tetratetracontane C44H90 23.567 618(M+
Squalene C30H50 26.56/26.716 410 (M+), 395, 367, 341, 299, 175, 149, 123, 105, 95, 69 Dinosterane C30H54 27.821 414 (M+), 301, 300, 273, 272, 177, 24-Ethylcholestane C29H52 30.042 400 (M+), 287, 286, 269, 268, 229, 117, 85 Benzamide - 5.719 193(M+), 178, 105, 77, 73 Phenylacetic acid - 6.06 208(M+), 193, 118, 91, 77 m-Hydroxybenzoic - 6.384 282 acid (as Di-TMS) (M+),267,223,193,147 ,73 -Methyl hippuric - 6.70 265 (M+), 250, acid 206, 190, 177, 105, 73, 51 6.749 208 (M+), 193, 180, H drox aceto henone 151, 105, 73 y y p Compound Mol. formulaRetention time,MS : m/z tR in min 2,4 - - 7.283 296 (M+), 281, 252, Dihydroxyacetophenon 239, 179, 73 a (as mono -TMS
Ribitol (as penta - 7.480 512 (M+), 413 (base -TMS) eak) p - Hydroxy - N - 7.666 223 (M+), 208, - 178, methyl benzamide 177 151 150 ' ' ' (as mono - TMS) 119, 73 Glucitol (as hexa-TMS)- 7.698 614 (M+), 485 (base peak , 319, 205 m - Hydroxyphenyl - 7.984 +
310 (M ), 295, 251, propionic acid (as 194, 117, 73 di -TMS) 3 - Hepten - 4 - - 9.551 390 (M+), 375 (base hydroxydioic acid peak), 259, 244, (as di-TMS) 117, 73 m - Cresol - 10.59 180 (M+ , 165, 79, 51 Uric acid (as tetra- 14.203 456 (M+), 441 (base -TMS) peak) 426, 383, 367, 147, 77, 73 3-Hydroxy-DBP - 18.702/19.851a284(M+), 269 (base peak), 241, 213, 183, 156, 94, 75 3,8- Dih drox -DBP - 23.910/25.165a372 M+ , 357, 327,73 p-Hydroxy-bis- - 32.533 344(M+), 329, 179, diphenyl methane 157, 135 (as di-TMS
Cholesterol - 36.283 458(M+), 443 (base peak), 368, 329, 247, 213, 129, 73 a GC-MS in two different conditions Table 6. Relative abundance of different groups of compoundsa found in marine invertebrate fossils and in shilajit Relative abundance Compound type Foraminiferab Molluscac Shilajitd H drocarbons 5.46 2.08 4.03 Fatt acids 15.10 14.77 11.56 Wax esters 1.33 2.05 3.88 Alk 1 g1 cerols 0.88 0.76 0.57 Alk lacyl 1 cerols 1.04 1.11 2.58 Triacylglycerols 2.11 3.54 5.03 Aromatic/phenolic 4.45 . 9.21 12.10 acids H drox aceto henones0.24 2.31 2.39 N, S-Heteroc clics 0.18 2.74 1.01 Ox genated DBPs 14.55 8.31 3.03 DBP-Chromoproteins 2.01 21.10 32.33 (DCPs Partially characterized7.22 11.60 8.64 com ds.
Humic substances (including polymeric45.43 20.42 12.85 com ds)e a By GC-MS analysis of corresponding methyl esters and TMS derivatives and other chromatographic and spectroscopic analyses b Mean of rel. abundance of compounds isolated from Nummulites, Alveolina, and Discocyclina fossils c Mean of rel. abundance of compounds isolated from fossils of Mollusca d Collected from the Kumaon region of the Himalaya Estimated by HPTLC
These findings suggest that marine invertebrates contribute to the formation of shilajit.
The marine invertebrates (Table 2) were investigated, followed by the isolation and characterization of DCPs in shilajit. Very similar DBP-carotenoproteins and other low Mw organic and coloring constituents (e.g., indigoids) were found in the marine invertebrate samples (Table 3-6).
The IR spectra of the mixture of DCPs isolated from shilajit and the Ammonites (Table 2) were similar. Also; the HPLC retention times of the major peaks and their PDA spectra were similar. The DCP-fractions on exhaustive organic solvent extractions followed by the usual work-up yielded astaxanthin, astaxanthin fatty acyl derivatives and canaxanthin. 3,8-Dihydroxy dibenzo-alpha-pyrone and the amino acids isolated from shilajit-DCPs, were also isolated from the Ammonite fossils (Table 2) from their acid hydrolysates.
The colored constituents of the DBP-chromoproteins from the Ammonites included mono-N-benzoyl indigotin, indirubin and isatin, presumably derived from the metabolism of the tryptophan moiety present in the DCPs. The browning of the proteins from the glycation of proteins, due to oxidative stress, was also discerned in the DCPs of both shilajit and the Ammonites fossils.
Preservation of color patterns on invertebrate fossils is a rare phenomenon but has been recorded throughout the Phanerozoic. The colored molecules comprising carotenoids, indigoids, and glycation of protein products, by the Maillard reaction, may form stable complexes by coordination with metal ions. Such infra-crystalline biomolecules act as a nucleation site for biomineralization. When limb muscles of dead marine animals decay, the vacated spaces are filled with minerals, such as pyrite (FeS2, CaSi03) before the thin organic cuticles that surround them have time to collapse or decay. The organic material forms a substrate for the nucleation of pyrite (and other minerals), which is ubiquitous in marine sediments. Precipitation is ensued as a result of diffusion of Fe and S into the cell. Pyrite does not replace the tissue directly but precipitates on surfaces and within spaces. Mutual stabilization of the coloured molecules and proteins in shilajit as well as in the fossils of Ammonites, was augmented by the participation of the DBPs Formula (I). This is the first demonstration of the natural occurrence of DBPs in complex association with chromoproteins. Whether this association is a general phenomenon, also in the living human and animal organisms, was also evaluated. Mixture of DCPs (pink colored) isolated from plasma of albino rats when compared with the corresponding fractions of DCPs from shilajit exhibited some striking similarities in respect of HPLC
peaks and their PDA spectra. Even greater similarities were observed between semi-purified DCP constituents by gel filtration over Sephadex G-50, obtained from shilajit and from the plasma of a human volunteer. Similar general HPLC patterns were observed with several healthy human subjects.
DCPs when administered to experimental animals showed dynamic turnover in respect of some of the key constituents (FIGURE 2). Likewise, the DBPs when administered orally (p. o.) to rat readily absorb and utilized them for the synthesis of DCPs and related conjugates. Oxygenated dibenzo-alpha-pyrones (DBPs), on being synthesized in the animal living systems from EPA, are transformed into several DBP-conjugates (HPLC-tR: 2.31, 2.99, 3.46 and 3.86 min). These components were also detected in DCPs, isolated from shilajit. A dynamic turnover of these constituents was observed (FIGURE 2) on oral administration of DCPs (200 mg/Kg b.w.) to albino rats, followed by HPLC analysis of the constituents in the corresponding RBC. From this and other observations, it is increasingly apparent that DCPs, which are also the constituents of animal tissues, act in the form of enzymes and hormones in regulating and fulfilling several biological functions.
DCPs may participate in a variety of functions in the producer organisms including protective-colorations which provide protection from radiation, electron transport, and enzyme activity and in their sustenance and development. DCPs, which have transport properties like those of the fulvic acids (FAs) of shilajit, can enter into recipient cells and elicit biological responses much more pronounced than free DBPs. Extensive pharmacological and immunological evaluations of DCPs have now demonstrated them to be 2-5 times more potent than any of the other constituents of shilajit as adaptogen and immunomodulator.
The systemic transformation of 3-hydroxy- and 3,8-dihydroxydibenzo-alpha pyrone (DBPs) into arginine and glycine phospholipid conjugates, their resultant metabolism, and the systemic assimilation/turnover of DCPs, when fed to rats through oral route, suggest the role of these compounds in energy storage in living systems.
Arginine phosphate plays an important role in the storage of energy in invertebrates;
the same role is played by creatine produced from a combination of argininephosphate and glycine phosphate in vertebrates. Creatine phosphate and arginine phosphate are reserves of phosphates of high energetic potential and, hence, the name 'phosphagens' given to these compounds as shown in Scheme 1.
ATP
(Synthesis catalysed by shilajit) ADP
Creatine/Arginine Phosphagens (in shilajit-DCPs) Scheme 1 An energetic coupling represents the energy storage reaction when ATP is present in excess and, inversely, the formation of ATP by the reverse reaction when the cells need the ATP. Should we consider the biosynthesis and balance of DBP-phosphagen complexes in living organisms as the indices of their energy status, then in the event of dearth of these phosphagens, administration (p. o.) of shilajit would replenish them.
The chromoproteins (DCPs), participate in a wide variety of functions in animal biological systems. DCPs have been encountered in the lowest form of animal 1 S organisms (foraminifera, in other marine invertebrates, and in haemolymph of termites), in higher animals (rodents, beaver, chimpanzee, sheep), and in man.
DCPs participate in electron transport [systemic ATP synthesis by DCPs is conceivable because oral administration of DBP produced creatine and conjugated product(s)] and oxido-reductase reactions; catalyze other enzyme activities (e.g., ATPase function as described in Cheesman, 1967); the larger abundance of DCPs in female invertebrate fossils of the Jurassic (e. g., Idiocyclocerus and Kamptokephalites spp.) (Table 2) compared to their male counterparts, found in the present study, suggests their role in the development and protection of the embryos. The superior (qualitative and quantitative) biological functions of the DCPs compared to those of EPA, DHA, and free DBPs formed from EPA/DHA are described in the sequel.
Thus, features of the isolation and use of DCPs are as follows:
1. Stabilization of protein and the colored molecules, carotenoids (e.g., astaxanthin and derivatives) and indigoids (e.g.,indigotin and indirubin) against different forms of stress and onslaughts.
2. Protective coloration, - the use of color as a means of concealment from prey-predator functions; utilization of the potently antioxidant pigments from deleterious effects of radiation; e.g., photo-oxidation of lipids, and from oxidative free radicals.
5 3. Development of the producer organisms. The large number of pigmented proteins which have been found in the ovaries of invertebrates and the higher abundance of these compounds in the female species compared to those of the male counterparts, suggest their function in the species development.
Lipoprotein complexes which have been noted in the blood/haemolymph of many invertebrates 10 may be involved in the transport of the carotenoids and other pigment molecules; the linkage to a protein making the fat-soluble pigments water-soluble. Hence the chromo-molecules in DCPs were found associated with both the lipid as well as the protein fractions of the complex molecules.
4. Development of embryos in invertebrates require carotenoproteins.
15 5. As simulator/surrogates of bio-energetics, e.g., ATP; creatine synthesis.
6. Immuno-modulator.
7. Captivators of oxidative free radicals, Reactive Oxygen Species (ROS), Reactive Nitrogen Species (RNS).
20 8. Scavengers/chelators of loose metal ions (Fe, Cu, Mn, W).
9. DCPs play a crucial vitalizer role in all organisms since the evolution of life on Earth.
The features of the isolation and use of DCPs provides a skin care, hair care, pharmaceutical, or nutritional formulation comprising a DCP composition present in an amount of about 0.05% to about 50% by weight. Also, the skin care or protection formulation can be in the form of a lotion, cream, gel or spray, wherein the DCP
composition is present in an amount of about 0.05% to about 5% by weight.
The features of the invention provide a pharmaceutical formulation comprising a DCP composition wherein the pharmaceutical formulation is in the form of a tablet, syrup, elixir or capsule.
The features of the invention provides a nutritional formulation comprising a DCP composition wherein the nutritional formulation contains about 0.5% to about 30% of the DCP composition by weight.
The features of the invention provides a veterinary formulation comprising a DCP composition wherein the veterinary formulation contains about 0.5% to about 30% of the DCP composition by weight.
The features of the invention provides a process for isolating DCP
S compositions from shilajit compositions comprising about 0.5% to about 10%
w/w dibenzo-alpha- pyronechromoproteins, the process includes the steps of 1)extracting shilajit successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration; 2) triturating the ethyl acetate and methanol insoluble material with hot water and then citrate buffer of pH 5.0; 3) filtering the combined extract-mixture to remove insoluble substances comprising polymeric humic materials, minerals and metal ion salts; 4) gradually saturating the combined aqueous filtrate with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating the combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering the DCPs and evaporating the filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from shilajit.
The features of the invention provides similar processes for extracting and isolating DCPs from fossils of ammonites, fossils of corals, and from invertebrates.
The features provide a method for treating chronic stress disorders, including administering to a patient in need thereof a therapeutically effective amount of a DCP
composition and a method for increasing cognition learning which includes administering a DCP composition.
The following examples will serve to further typify the nature of the invention.
Extraction and isolation of DCPs of shilajit Shilajit (rock powder) was extracted successively with hot ethyl acetate and methanol to remove free organic compounds which were subsequently analyzed comprehensively (Tables 3-6). The marc (ethyl acetate- and methanol-insoluble material) was triturated with hot water and citrate buffer (pH S.0) and then filtered.
The marc was analysed for inorganic minerals and humic substances. The aqueous solution was differently saturated with ammonium sulfate (25%, 50%, 75%
and 100%) when DCPs of different complexities were precipitated as purple-brown solid. The solid residues were subjected to Sephadex gel filtration and electrophoresis for further purification of DCPs. The same general procedure was followed for the isolation of DCPs from the marine samples. In the precipitation of DCPs from aqueous solutions, however, one variation constituted addition of acetone, instead of ammonium sulfate and to isolate DCPs from acetone-insoluble and soluble fractions in the usual way.
Extraction and isolation of DCPs of marine invertebrate fossils (general procedure) In a typical experiment, fossils of Nummulites (foraminifera, GSI type No. 10772) were dried, finely powdered and then extracted with hot ethyl acetate to remove low Mw organic compounds (free oxygenated dibenzo-alpha-pyrones, hydroxyacetophenones, aromatic acids etc., cf. Tables 3-6) as the ethyl acetate-soluble fraction. The mart (insoluble in ethyl acetate) was further extracted with O.1N HCI.
The aqueous acidic extract was evaporated. The residue was dissolved in minimum volume of distilled water. The aqueous solution was divided into two parts.
One part was differently saturated with ammonium sulfate and to the other part, acetone was gradually added. Addition of both ammonium sulfate and acetone precipitated mixtures of oxygenated dibenzo-alpha-pyrone chromoproteins (DCPs) as light brown solid. The acetone-soluble fraction, on evaporation also afforded a further crop of DCPs of lesser complexities. These compounds were subsequently subjected to chromatographic (HPLC) and spectroscopic (IR, 1H-NMR) analyses to establish their general identities with DCPs.
Extraction of living marine invertebrates (general procedure) Living marine invertebrates mainly molluscs (Telescopium, Cerethedia etc.) were collected from coastal region of Bay of Bengal and brought to the laboratory as live specimen. Each specimen was sacrificed and body flesh was taken out from shell. Body flesh was then extracted with hot ethylacetate to remove low molecular weight organic compounds and lipids. The mart (EtOAc insoluble portion) was further extracted with Bligh & Dyer solvent system [CHC13: MeOH (1:2) as initial solvent; CHC13: MeOH: H20 (1:2:0.8) as intermediate solvent and CHCl3: MeOH
(1:2) as final solvent]. The Bligh & Dyer (B&D) solvent was evaporated under reduced pressure. The B&D extractive was dissolved in minimum volume of distilled water. The aqueous solution was divided into two portions. One portion was gradually saturated with ammonium sulphate and to the other portion, acetone was gradually added. Addition of both ammonium sulphate and acetone precipitated mixtures of DCPs (oxygenated dibenzo-alpha-pyrone chromoproteins) as off white solid. These compounds were analyzed by different chromatographic (HPLC) and spectroscopic (IR, 1H-NMR,GC-MS) techniques to establish their identities with shilajit DCPs.
Separation and Partial Characterization of DCPs (I and II) Sodium dodecyl sulfate polyacrylamide gel electrophoresis was carried out by the method of Weber and Osborn (1969) with 10% acrylamide in presence of 0.1%
(w/v) SDS. The sample was preheated at 100° C for 3 minutes in presence of 2-mercaptoethanol and 3% SDS. Tris-glycine buffer containing 0.1% SDS (pH 8.4) was used as running buffer. Bromophenol blue was used as tracking dye.
Electrophoresis was performed at a constant current of 120V, 40 mA for 90 min.
A
pinkish-orange band appeared towards the top (DCP-n followed by bromophenol blue and then a yellow band (DCP-II). After the run was over, these three bands were cut with a fine blade and homogenized, separately, in 1.5 ml distilled water in a mortar-pestle. Each homogenate was decanted into a micro-centrifuge tube and centrifuged at 7000 rpm for 10 minutes. Each supernatant was divided into two parts and evaporated under vacuum. One part of the sample (ca. 50 pg) was dissolved in HPLC
running solvent (water:acetonitrile:orthophosphoric acid = 67:32:1) and analysed by HPLC. The other part was subjected to lipase reaction (see EXAMPLE 5).
The DCP-I compound was obtained as a pink colored powder; pH (1%
aqueous solution) 8.02; N, 17.8%; metal ions (in ppm) Fe, 186.3; Cu, 8.8; Zn, 23.4.
The DCP-II compound was obtained as a light brown powder, pH ( 1 aqueous solution) 7.8; N, 16.4%; metal ions (in ppm) Fe, 262.4; Zn, 48.7.
Further purification of the two chromoproteins was carried out by Sephadex ion exchange on DEAE-Sephadex G-50, using phosphate buffer (pH 7.2). Gel electrophoresis (10% SDS, thickness 1.5 cm; constant current 20 mA, tris-glycine buffer, pH 8.3) showed two major bands in each of DCP-I, 2-S KD and DCP-II, 10-KD; with several lighter bands at higher Mw ranges.
Both DCP-I and DCP-II exhibited HPLC and spectroscopic (IR, 1H-NMR) characteristics typical of DBP-carotenoproteins.
Lipase reaction of DCPs The sample (ca.50 wg) was dissolved in 0.5 ml 1M tris-buffer of pH 8Ø100 g1 (2.2%) CaC12.2H20 and 250 ~,1 (1%) bile salts were added to each sample.
Working solution of lipase (Hog pancreatic lipase, Sigma, 1 mg in 2 ml tris-buffer) was then added to each sample. The mixtures were agitated by magnetic stirrer for three hours at 37° C. After the incubation period, 1 ml ethanol and 1 ml 6N HCl was added to the mixtures to stop the reaction. The hydrolyzed products were extracted by diethyl ether and dried over anhydrous sodium sulfate. The remaining portions were evaporated on water bath in porcelain basin. The residues were dissolved in minimum volume of HPLC solvent (water:acetonitrile:orthophosphoric acid =
67:32:1) and 20 w1 was injected into HPLC for analysis. Collective ether extractives, after lipase hydrolysis, was also analysed in HPLC in the same solvent system to characterize the nature of lipoidal compounds.
In the HPLC chromatograms of DCPs, precipitated from aqueous solution of shilajit by differently saturating with ammonium sulfate, a large number of peaks appeared in the 75 and 100 percent-saturated fractions (Fig. 3). This observation suggested that shilajit DCPs are replete with relatively low Mw lipoproteins (like chylomicrons/lipocalins). However, tR 1.5 min signal (Fig. 3) suggested that higher Mw proteins, like B-48, might also occur in DCPs. The presence of adherent ligands, particularly DBPs, was also suggested.
Another observation was the association of DBPs as ligands in DCPs (Fig. 4).
In this figure, PR-25, -50, -75 and -100 denote respective ammonium sulfate precipitated protein fractions. Note that in the PR-50 and -75, the abundances of 3,8 dihydroxydibenzo-alpha-pyrone are very high suggesting that the DBPs are preferentially associated with low/medium MW lipoproteins.
Determination of amino acids The mixture of amino acids produced in the acidic hydrolysates of DCPs was converted into trimethylsilyl derivatives (O-/N-TMS) and then subjected to GC-MS
analysis by using corresponding markers, similarly prepared with the standard amino acids.
Determination of creatine 5 This method, based on the color reaction developed by creatine in the presence of diacetyl and a-napthol, was described by Barrett (1936). Briefly, to a neutral solution of the test sample, containing not more than 60 ~g of creatine, 2 ml of 1% a-napthol in alkali was added followed by 1 ml of diacetyl ( 1 % solution diluted to 1:20 before use). The solution was shaken, and the color was measured after 30 min at 525 10 m~.
Determination of arginine Arginine, isolated from DCPs by selective degradation (lipase), was decomposed by arginase (5 to 10 units/ml) to ornithine and urea and were assayed 15 colorimetrically (using acid mixture, - 1 vol. H2S04; 3 vol. syrupy H3P04;
1 vol. H20;
urea standard, 50 ~,g/ml in H20; and a-isonitrosopropiophenone, 4 g. in 100 ml of 95% ethyl alcohol).
Comparative study of the effects of shilajit constituents on chronic stress 20 A comparative study of shilajit bioactive constituents from EPA, DHA, DBPs and DCPs, was carned out to determine their adaptogenic potency against chronic stress (CS) in albino rats. It is now increasingly becoming evident that CS of a mild but unpredictable nature which the animal is unable to cope with (inescapable stress), is clinically more relevant than acute stress even when the latter is severe in nature. It 25 is believed that chronic, unpredictable, and inescapable stress resembles the situation faced by an individual that ultimately results in chronic stress- induced physiological perturbation and disease.
Animals The investigation was carried out on CF strain albino rats, of either sex (140-180g), housed in colony cages at an ambient temperature of 25 t 2° C, with a 12h. light /12h. dark cycle. Experiments were conducted between 0900 and hrs.
EPA, Eicosapentaenoic acid DHA, Docosahexaenoic acid DBPs, 1:1 mixture of 3- hydroxy - and 3,8 -dihydroxydibenzo-alpha-pyrone DCPs, DBP-chromoproteins Induction of chronic stress The procedure of Armario et al (1993) was followed. Briefly, rats were randomly assigned to control or stress groups. Those assigned to the stress groups were subjected to 1h foot shock, through a grid floor, every day for 14 days.
The duration of each shock (2mA) and the intervals between the shocks were randomly programmed between 3-5 sec. and 10-110 sec., respectively, to make the stress unpredictable. The shock chamber had high walls which made escape from shock impossible.
Test compounds and Vehicles EPA (Aldrich, Milw.), DHA (Sigma), DBPs and DCPs were separately suspended/ dissolved in 0.3% carboxymethylcellulose(CMC) in distilled water and administered orally (p.o.) , for 14 days , starting on day 1, 60 min prior to electroshock. Control animals received only the vehicle in either unstressed or the stressed rats for the same period in a volume of 2.Sm1/kg, p.o. Estimations were conducted on day 14, one hour after the last stress procedure and two hours after the last test compound or vehicle was administered.
Determination of intensity of chronic stress effects Gastric ulcerations (Bhattacharya et a1.,1987). On day 14, rats were killed by decapitation the stomach was split open along the greater curvature and the numbers of discrete ulcers were noted. The severity of ulcers was scored, after histological confirmation, as 0 = no ulcers; 1 = changed limited to superficial layers of mucosal with no congestion; 2 = half the mucosal thickness shows necrotic changes; and 4 =
complete destruction of mucosa with hemorrhage. Thereafter, the pooled ulcer score was calculated according to the method of Bhattacharya et al. (1987).
Adrenocorticoid activity Adrenal gland ascorbic acid (Zenker and Bernstein, 1958) and corticosterone concentrations (Selye, 1936), and plasma corticosterone levels (Selye, 1936) were determined to substantiate the validity and intensity of the stress procedure adopted.
Results and discussion Chronic stress (CS) significantly increased the incidence, number and severity of gastric ulcers. All the four test compounds had, albeit in different degrees, dose-related anti- ulcerogenic effect. The extent of the anti-ulcerogenic effect was in the S order: DCPs>DBPs>DHA~EPA as follows in Table-7.
Table-7: Effects of shilajit constituents on chronic stress (CS) induced gastric ulceration in albino rats.
Treatment groups n Ulcer o No. of ulcersSeverity of ulcers (mg/kg, . o. incidence /o Chronic stress (CS) 12 100 19.8 ~ 3.0 32.4 ~ 5.1 EPA~S~ + CS 10 70 16.5 t 3.4 28.3 ~ 7.7 EPA ~,o~+ CS 10 60 14.3 t 4.4 26.4 ~ 6.2 DHA ~5~ + CS 10 70 15.8 ~ 4.0 28.1 ~ 5.9 DHA ~~o~ + CS 10 60 14.7 t 3.8 25.0 ~ 5.2 DBPs ~5~ + CS 10 SOa 11.7 ~ b 3. 13.2 t 3.0b la DBPs ~lp~ + CS 10 40a 8.2 ~ 2.2b 9.7 ~ 2.0b DCPs ~5~ + CS 10 30a 9.0 ~ 2.8b 12.1 ~ 2.36 DCPs ~lp~ + CS 10 20a 7.3 ~ 1.86 8.1 ~ 2.06 ° p < 0. 05 vs CS group ( chi square test); b p < 0. 05 vs CS group.
Chronic stress (CS) caused marked depletion of adrenal gland ascorbic acid and corticosterone concentrations with concomitant increase in plasma corticosterone levels. These findings also suggest that the stress protocol used in this study induced pronounced stress. As expected, all the four test compounds (EPA, DHA, DBPs, DCPs) reversed, to different extents, these stress- induced adverse effects in a dose related manner; their stress- attenuating actions, in doses used, had no per se effect on the indices of stress investigated as follows in Table 8.
Table-8. Effects of Shilajit constituents on chronic stress (CS) induced alteration of adrenal gland ascorbic acid and corticosterone concentrations and plasma corticosterone level Groups Adrenal ascorbicAdrenal Plasma m k . o. n acid 100m corticosteronecorticosterone ( ~ g> P ) (~t~ g) (w1~100mg) (p~dL) Vehicle 8 300.2 t 38.4 4.4 + 0.7 14.0 + 1.3 EPA ~5~ 6 308.8 t 28.7 5.7 + 1.4 15.0 + 0.6 EPA~IO~ 6 310.5+26.0 5.20.8 15.5+1.1 DHA ~5~ 6 309.4 + 30.4 4.8 ~ 1.2 15.0 t 0.9 DHA ~lo~ 6 308.9 + 27.4 5.5 ~ 1.0 14.7 ~ 1.0 DBPs ~5~ 6 309.1 ~ 25.8 5.0 t 1.3 15.7 + 1.4 DBPs ~lo~ 6 315.5 + 25.5 5.4 t 1.7 14.9 + 1.5 DCPs ~5~ 6 308.5 + 25.5 4.9 + 0.8 14.7 + 1.0 DCPs ~,o~ 6 312.5 t 26.0 5.1 t 1.5 15.3 t 1.5 Chronic stress 12 114.7 + 16.0a 1.7 + 0.5a 28.0 + 3.0a (CS) EPA~S~+CS 6 138.5+18.2 2.3+0.8 22.1+2.9 EPA ~io~ + CS 6 144.2 + 14.7b 2.9 + 0.7b 18.3 ~ 1.86 DHA ~5~ + CS 6 140.7 t 20.5 2.5 + 1.0 22.5 ~ 3.5 DHA ~lo~ + CS 6 148.0 t 16.7b 2.8 + 1.0b 17.9 + 0.9b ' DBPs ~5~ + CS 6 173.4 + 18.2b 3.0 + 1.4b 17.3 + 0.76 DBPs ~lo~ + 6 198.5 + 20.76 3.2 ~ 1.1b 16.8 ~ 1.06 CS
DCPs ~5~ + CS 6 200.3 ~ 25.2b 3.5 + 1.06 14.7 ~ 1.16 DCPs ~,o~ + 6 242.2 + 27.36 3.9 + 0.86 14.0 ~ 1.8b CS
a p < 0. OS vs vehicle- control group; b p < 0. OS vs CS group The effects of DBPs and DCPs on chronic stress induced suppression of humoral immunity in rats (Table-9) and in rat brain frontal cortex SOD, CAT, GPx and LPO activities (Table-10) established the major bioactivity-contribution of DCPs to shilajit.
Table-9: Effects of DBPs (1:1 mixture of 3-OH and 3,8-(OH)z dibenzo-alpha-pyrones) and DCPs on CS -induced perturbations in rat brain frontal cortex SOD, CAT, GPx and LPO activitiesa.
Treatment SOD (pg/mg CAT (~,g/mg GPX (pg/mg LPO (n mol protein) protein) protein) ~ B ej S/gm (mg/Kg, p.
o. ) Vehicle 16.81.4 20.21.9 0.080.02 3.320.6 Chronic stress30.91.66 9.60.8b 0.02O.OIb 7. 40.96 CS
DBPs (5) 22.00.9 12.80.6~ 0.030.009 5.460.7~
+ CS
DBPs (10) + 20.40.8' 14.60.8 0.050.008 4.320.8 CS
DCPs (1.0) + 40.9~ 15.41.2 0.050.06 4.420.09 CS .
DCPs (2.0) + 41.1 17.80.9 0.07O1 1.220.08 CS .
a = Data are means ~ SEM; n= 8 to 10 replicates.
b = p < 0.05 vs vehicle control group.
= p < 0.05 vs chronic stress group (CS).
SOD, superoxide dismutase, CAT, catalase.
GPx, glutathione peroxidase.
LPO, lipid peroxidation Test drugs were administered 14 days concomitant with stress procedure.
Table-10: Effects of DBPS and DCPs on chronic stress-induced suppression of humoral immunity in ratsa.
Treatment groupsDetectable level of haemagglutination titre to SRBC
(mg/Kg, p. o. 1 /2 -1/16 1/32 - 1/128 1/256 -1/512 ) Vehicle - 74 26 Chronic stress 62b 38b -DBPs(S) + CS 48 52 -DBPs (10) +C5 32 68 -DCPs (1.0) +CS 26 62 -DCPs (2.0) +CS 22 72 -result are expressed in %; n = 8 to 10 replicate;
b = p < 0.05 vs vehicle-treated control group.
5 ° = p < 0.05 vs chronic stress group (CS).
(Chi-square test). Animals were bled on day 14 after sensitization with SRBC
on day 1.
Effect of DCPs on Arachidonic Acid Metabolism 10 The anti-inflammatory effects of shilajit and its major bioactive constituents, DCPs, were evaluated by using arachidonic acid (AA) metabolism. The effect of shilajit on AA metabolism was tested in isolated human neutrophils. Shilajit and DCPs both inhibited the biosynthesis of AA-lipoxygenase pathway products, namely, leukotriene-B4 (LTB4), 5-hydroxyeicosatetraenoic acid (5-HETE), 12-15 hydroxyeicosatetraenoic acid (12-HETE) and also inhibited the biosynthesis of the cycloxygenase product, 12-hydroxyheptadecatrienoic acid (12-HHT), in a dose dependant manner. Maximum inhibitory effects were observed at a concentration of 50 ~,g/ml of shilajit, while in case of DCPs, it was only 10 ~g/ml. A 1:4 combination of 3,8-dihydroxydibenzo-alpha-pyrone (DBP) and fusoms exhibited similar equi-20 active effect at a concentration of 20 ~g/ml. Fusoms of shilajit are used as an efficient systemic drug delivery agent (Ghosal, 2003). These findings suggest that the inhibition of synthesis of leukotrienes (and equivalents) by shilajit and its major bioactives (DCPs) is responsible for their therapeutic action, e.g.,in the treatment of bronchial asthma.
The results as shown in Tables 7 and 8 suggest that DBPs (1:1 mixture of 3-hydroxy - and 3,8 -dihydroxydibenzo-alpha-pyrone) are biologically more active than either of its precursors, namely, EPA (eicosapentaenoic acid) or DHA
(docosahexaenoic acid) while DCPs are the most active among the bioactive agents of S shilajit. Similar graded effects of DBPs and DCPs were observed on chronic stress (CS)-induced perturbations in rat brain antioxidant enzymes and LPO activities (Table-9) and CS-induced suppression of humoral immunity in rats (Table-10).
The Significance of DCPs in living system and the fate of DCPs after oral administration to experimental animals are also shown.
Antioxidative Actions of DCPs Inhibition of Fe-ADP-ascorbate induced lipid peroxidation (LPO) in rat brain by DBP and DCPs Albino rats (Sprague Dawley strain) were sacrificed by cervical dislocation 1 S and decapitation. Brains were dissected out and 10% w/v homogenate was prepared in 0.15 M KCI. The brain homogenate was centrifuged at 1500 rpm for 10 minutes and the supernatant was used for the study. The incubation mixture contained in a final volume of 1 ml., brain homogenate (500 p1), distilled water (100 w1) or test . compounds dissolved in solvents at different concentrations (10 to 100 pg/ml of the final volume). Peroxidation was initiated by adding FeCl3 (100 pM), ADP (1 mM) and ascorbate (100 ~M) to give the final concentration stated. After incubating at 37° C for 30 minutes, the reaction was stopped by adding acetic acid buffer (1.5 ml, pH 3.5) and thiobarbituric acid solution (1.5 ml, pH 7.4) to 1 ml of LPO
mixture. The reaction mixture was heated at 85° C for 30 minutes, cooled, centrifuged (2000 rpm for 10 minutes) and the absorbance of the supernatant was measured at 532 nm.
ICso values were calculated in the usual way by plotting the concentration of the test compounds versus percent inhibition of LPO.
Metal-ion Chelating and Scavenging Actions of DCPs This was determined by the stability of metal-ion complexes/conjugates of DCPs and their capacity to scavenging/chelating loose metal ions.
The ion-exchange equilibrium method of Schnitzer and Skinner (1966) was used for the abovementioned determination. Briefly, amounts of DCPs ranging from 10 to 50 mg were weighed into 50 ml volumetric flasks and dissolved in approximately 40 ml of distilled water. To each flask, 5 ml of 1N-KCl solution was added. One-gram quantities of K-saturated Dowex-50 resin (20-SO mesh, Bio-RAD
Laboratories) were weighed into 125 ml of ground glass-stoppered Erlenmeyer flasks.
The solution containing the natural DCP-metal ion conjugates (Fe, Cu, Zn), admixed with KCI, were transferred to these flasks and shaken at 241° C for 1 hour. In a separate experiment, known amounts (approx. 500 p,g) of aqueous solutions of MnCl2, MoCl3 and WC14 were added separately, to aqueous solutions of the DCP-KCI. The mixtures were shaken as before and the stability constants were determined as follows. The exchange resin was then removed by filtration. The filtrates and washings, containing metal ions, Fe2+, Cu2+, Zn2+, and those of the added metal ions, were analyzed by Atomic Absorption Spectroscopy (Techtron AA-3 Atomic Absorption Spectrophotometer).
At pH 3.5, log stability constants for the different DCP-metal ion complexes 1 S were: DCP-Cu, 3.44; DCP-Fe, 2.83; DCP-Zn, 1.47. The order of stability of the different metal ions was (expressed in the decreasing order): Cu2+>
Fe2+>Mn3+>Znz+>Mo3+>W4+.
The results as shown in Tables 7 and 8 suggest that DBPs (1:1 mixture of 3 hydroxy - and 3,8 -dihydroxydibenzo-alpha-pyrone) are biologically more active than either of its precursors, namely, EPA (eicosapentaenoic acid) or DHA
(docosahexaenoic acid) while DCPs are the most active among the bioactive agents of shilajit. Similar graded effects of DBPs and DCPs were observed on chronic stress (CS)-induced perturbations in rat brain antioxidant enzymes and LPO activities (Table-9) and CS-induced suppression of humoral immunity in rats (Table-10).
Stress begets oxidative stress. The antioxidant actions of DCPs are pronounced as shown in Tables 11 and 12 which shows the significance of DCPs in living systems and the fate of DCPs after oral administration in experimental animals.
Table 11. Effect of DBP and DCPs on LPO
*AcMe pptd. Note the significant antioxidant effect of DCPs Table-12. Antioxidant activity of DCPs.
ROS Captodative RNS Captodative Activity Activity .
(ICso) (ECSO) In terms of In terms of protein protein content of DCPs content of DCPs Total DCPs Total DCPs (g0o~o protein (600~o protein in in DCPs DCPs) l5mcg/ml 9 ~g/ml 80.80 ~g/ml 48.48 ~g/ml Note: In terms of ~M of amounts, the antioxidant activities of DCPs are highly significant.
Personal Care / Cosmetic Formulations A. SKIN REJUVENATING (0/W) LOTION
Ingredients % w/w Phase A
Polyglyceryl-3 Methyl Glucose 3.50 Distearate Glyceryl Stearate, PEG-100 Stearate2.50 Dicapryl ether 5.00 Coco-Caprylate/Caprate 5.00 Propylene Glycol Dicaprylate/Dicaprate3.00 Almond Oil ~ 2.00 Cetyl alcohol 1.50 DCPs (present invention) 2.00 Phase B
Glycerin 3.00 Propylene glycol 3.00 Allantoin 0.20 Methylparaben 0.15 Water, deionized q.s.
Phase C
Phenoxyethanol and Isopropylparaben0.50 and Isobutylparaben and Butylparaben Total 100.00 Procedure Combine A, stir and heat to 65° C. Combine B, stir and heat to 65 ° C. Add A
to B while stirnng. Homogenize at moderate speeds to avoid foaming, while allowing mixture temperature to cool to 40° C. Add C, homogenize. Stir gently until mixture is homogenous.
B. SUNSCREEN O/W LOTION (SPF 15) Ingredients % w/w Phase A
Propylene Glycol Isoceteth-3 5.00 Acetate Octyl methoxycinnamate 7.50 Benzophenone-3 3.00 Homomenthyl Salicylate 7.00 Steareth-2 0.40 Steareth-10 0.80 Acrylates/C. sub. 10-30 Alkyl 0.18 Acrylate Crosspolymer Synthetic Wax 0.80 Dimethicone 1.00 DCPs (present invention) 1.00 Phase B
Demineralized water q.s.
Phase C
Demineralized water 19.82 Phenylbenzimdazole sulfonic acid1.00 Propylene glycol 2.00 Triethanolamine 0.90 Propylene Glycol and DMDM Hydantoin1.00 and Methylparaben Total 100.00 Procedure Combine A, stir and heat to 80° C. Heat B to 80° C. Add A to B
while stirnng 5 with a propeller mixer. Continue stirnng A/B for 20 minutes while maintaining the temperature between 70-75° C. Combine C, heat and stir to 45° C
until dissolved.
Add C to A/B with agitation. Qs water. Gently homogenize A/B/C allowing mixture to cool to room temperature. Adjust pH to ~6.5, if necessary, with TEA. Use high shear spray device to dispense.
C. LIQ UID FOUNDATION
A liquid foundation having the following formulation was prepared according to the following method.
S. No. Ingredients % w/w 1 Lanolin 7.00 2 Liquid Paraffin 5.00 3 Stearic Acid 2.00 4 Cetanol 1.00 Glycerin 5.00 6 Triethanolamine 1.00 7 Carboxy Methyl Cellulose0.70 8 Deminaralized Water q.s.
9 Mica 15.00 Talc 6.00 11 Titanium Oxide 3.00 12 Coloring Pigment 6.00 13 DCPs (present invention)0.50 14 Ultraviolet Screening q.s.
Agent Perfume q.s.
5 Procedure A. The components (1) to (4) were mixed and dissolved together.
B. The components (9) to ( 12) were added to and uniformly admixed with the foregoing mixture A.
C. The components (5) to (8) were uniformly dissolved together and the resulting 10 mixture was maintained at 70° C.
D. The foregoing mixture C was added to and uniformly admixed with the foregoing mixture B to give an emulsion.
E. After cooling the foregoing mixture D, the components (13) to (15) were added thereto to give a liquid foundation.
15 It was found that the liquid foundation prepared in Example 3 has excellent stability over time. Application of this foundation to the skin could prevent the occurrence of any sun-induced wrinkle.
D. MOISTURE RECOVERY BODY LOTION
Ingredients % w/w Phase A
Demineralized Water 76.45 PVM/MA Decadiene Crosspolymer 0.25 Disodium EDTA 0.15 Hexylene Glycol 2.00 Allantoin 0.10 Phase B
Glyceryl Stearate (and) Behenyl 3.00 Alcohol (and) Palmitic Acid (and) Stearic Acid (and) Lecithin (and) Lauryl Alcohol (and) Myristyl Alcohol (and) Cetyl Alcohol Isopropyl myristate 3.00 Octylhydroxy Stearate 5.00 Isostearyl Neopentanoate 4.00 Phase C
Sodium Hydroxide (10% Aq. Soln.) 0.40 Phase D
Glycerin (and) Glyceryl Polyacrylate2.00 Phenyl Trimethicone 1.00 Cyclopentasiloxane 1.00 DCPs (present invention) 0.50 Phase E
Propylene Glycol (and) Diazolidinyl0.50 Urea (and) Iodopropynyl Butylcarbamate Phenoxyethanol (and) Isopropylparaben0.50 (and) Isobutylparaben (and) Butylparaben Fragrance 0.15 Total 100.00 Procedure:
1. Combine ingredients in Phase A and heat to 80° C for 45 minutes with mixing.
2. Combine ingredients in Phase B. Heat and mix to 75° C - 80° C
3. Add Phase B to Phase A under homogenization. Homogenize until uniform.
4. Add Phase C to Phases A&B. Take off homomix, start cooling.
Switch to propeller mixing to 40° C.
5. Add Phase D ingredients at 40° C, one by one and mix well between each addition.
6. Add Phase E at 35° C. QS for water loss.
E. HAIR SHINE OIL
Ingredients % w/w Phase A
DCPs (present invention) 0.25 Lauryl Lactate 3.00 Phase B
SD Alcohol 40-B (200 proof 16.75 C12-15 Alkyl Benzoate 10.00 Cyclopentasiloxane 59.00 Phenyl Trimethicone 10.00 Phenoxyethanol (and) 1.00 Isopropylparaben (and) Isobutylparaben (and) Butylparaben Total 100.00 Procedure:
1. Add DCPs to Lauryl lactate in a small mixing vessel. Heat the mixture to 60-70° C. Mix well with slow agitation until homogenous. Cool down to 30-35° C
while agitating.
2. Add Alcohol into a separate, larger vessel.
3. When Phase A is at 30-35° C add Phase A to the alcohol. Mix well until homogenous. Add remaining ingredients in order with thorough mixing between each until homogenous.
4. Add the preservative. Mix well until homogenous.
F. SKIN BRIGHTENING / LIGHTENING LOTION FOR FACE
Ingredients % w/w Phase A
x Water (demineralized 65.97 Disodium EDTA 0.10 Propylene Glycol 2.00 Sorbitol 2.00 Sodium Laur 1 Sulfate 0.15 Phase=B - .~.~. =v- _~;.
G1 ceryl stearate 5.00 Stearic acid 1.00 Avocado oil 10.00 Almond oil 5.00 Beeswax 1.50 Phase ,G __ ,m ~--_ _: ~ ,.~_ __ . ~ ._. . -~ -:~~...
.. . ~ .~r=
Water (demineralized) 5.00 DCPs (present invention)1.00 ," _ ~ _:.
_ _ ~ ..
_ ~ ~ ~c Phase D
~_ ~
Triethanolamine 0.28 Phase~E ~. ~ ;
Propylene glycol, DMDM 1.00 H dantoin, Meth 1 araben Total ~ 100.00 Procedure Combine A and heat to 70-75° C. Combine B and heat to 70-75° C. Add B to A while stirring. Add phase C at 30° C. Adjust pH to S.0-6.0 with phase D. Add phase E. Mix until uniform.
Pharmaceutical/ Nutritional Formulations A. TABLETS AND CAPSULES OF THE INVENTION
Ingredient Quantity per Tablet/Capsule 1.DCPs 0.10-50.00% by weight 2.Avicel pH 101 200.00 mg 3.Starch 1500 189.00 mg 4.Stearic acid, N. F. (powder) 8.60 mg S.Cab-O-Sil 2.00 mg Note: The target weight of tablet/capsule is 400 mg; Avicel pH 101 and Starch may be adjusted suitably to reach the target weight. The blended material can be filled into appropriate capsules.
B. ANTI-STRESS SUPPORT TABLETS/CAPSULES OF THE INVENTION
Ingredient Quantity per Tablet/Capsule 1. DCPs 0.10-50.00% by weight 2. Cellulose q. s.
3. Magnesium stearate q. s.
4. Gelatin q. s.
C. CARDIO-VASCULAR SUPPORT TABLETS OF THE INVENTION
Ingredient Quantity per Tablet/Capsule 1. DCPs 10.0 - 50.00% b wei ht 2. Vitamin A (Beta Carotene) 45,000 IU
3. Vitamin B-1 (Thiamin) 25 mg 4. Inositol Hexanicotinate 50 mg 5. Vitamin B-6 (Pyridoxine HCL) 25 mg 6. Vitamin B-12 (Cyanocobalamin) 500 mcg 7. Folic Acid 800 mcg 8. Vitamin C (Magnesium Ascorbate) 150 mg 9. Vitamin E D-alpha Tocophery (Natural)400 IU
10. Copper (Sebacate) 750 mcg 11. Magnesium (Ascorbate, Taurinate, 30 mg and Oxide) 12. Potassium (Citrate) 10 mg 13. Selenium (L-Selenomethionine) 200 mcg 14. Silica (from 400 mg of Horsetail 10 mg Extract) Other Ingredients and Herbs:
15. Coenzyme Q10 (Ubiquinone) 10 mg 16. L-Carnitine L-Tartrate 50 mg 17. Hawathorn Berry Extract 40 mg 19. Grape Seed Extract lOmg 20. L-Proline 50 mg 21. L-Lysine (HCL) 50 mg 22. N-Acetyl Glucosamine 50 mg 23. Bromelain (2,000 GDU per g) 120 mg 24. Taurine (Magnesium Taurinate) 50 mg 25. Inositol (Hexanicotinate) 10 mg D. MULTI-VITAMIN & MINERAL SUPPLEMENT TABLETS OF THE
INVENTION
Quantity per Ingredient Tablet 1. DCPs 0.50-30.00% by weight 2. Vitamin A (beta carotene) 25,000 IIJ
3. Vitamin A (palmitate) 10,000 ILT
4. Vitamin B-1 (Thiamin Nitrate) 10 mg 5. Vitamin B-2 (Riboflavin) 10 mg 6. Inositol Hexanicotinate, Niacinamide20 mg & Niacin 7. Vitamin B-5 (Calcium D-Pantothenate)10 mg 8. Vitamin B-6 ((Phyridoxine HCL) 10 mg 9. Vitamin B-12 (Cyanocobalamin) 200 mcg 10. Biotin 500 mcg 11. Folic Acid 800 mcg 12. Vitamin C 180 mg (Magnesium, Manganese & Zinc Ascorbates) 13. Fat-Soluble Vitamin C 20 mg (from 476 mg of Ascorbyl Palmitate) 14. Vitamin D-3 (Cholecalciferol) 400 ILJ
15. Vitamin E D-alpha Tocopheryl (Natural)600 ILT
16. Boron (Amino Acid Chelate) 2 mg 17. Calcium (Succinate, Carbonate, 20 mg Malate) 18. Copper (Sebacate) 1 mg 19. Iodine (from Kelp) 150 mcg, 150 mcg Magnesium (Ascorbate, Oxide, Succinate) 20. Manganese (Ascorbate) 30 mg 21. Molybdenum (Amino Acid Chelate) 300 mcg 22. Potassium (Succinate, alpha-Ketoglutarate)10 mg 23. Selenium 250 mcg (L-Selenomethionine & Sodium Selenite) 24. Zinc (Zinc Monomethionine & Ascorbate)10 mg Other Ingredients and Plant antioxidants: N-Acetyl Cysteine, Succinic Acid (Free Form), Choline (Bitartrate), Inositol (Hexanicotinate and Inositol), N-Acetyl Glucosamine, DMAE (Bitartrate), N-Acetyl L-Tyrosine, Coenzyme Q 10, Alpha-Lipoic Acid, Quercetin, Milk Thisle Seed Extract, Grape Seed Extract, Ginkgo Biloba, Bilberry Extract.
E. ANTI-DIABETIC SUPPORT TABLETS/CAPSULES OF THE INVENTION
Quantity per Ingredient Tablet/Capsule 5 1. DCPs 0.10-50.00% by weight 2. Vitamin B-6 (as Pyridoxine 10 mg HCI) 3. L-Arginine 50 mg 4. L-Lysine Monohydrochl oride50 mg 5. Cellulose q.s.
10 6. Magnesium stearate q.s.
7. Gelatin q.s.
F. WEIGHT LOSS SUPPORT TABLETS
OF THE INVENTION
Quantity per Ingredient Tablet/Capsule 1. DCPs 0.10-50.00% by weight 2. Garcinia Cambogia Extract 60 mg 3. Bitter Orange Peel Standardized 20 mg Extract 4. Green Tea 10 mg 5. Cayenne 15 mg 6. Mustard Seed 10 mg 7. Ginger Root 10 mg 8. Piper nigrum 10 mg 9. Acetyl L-Carnitine 10 mg 10. Niacinamide 10 mg 11. Vitamin B-6 (Pyridoxine HCL) 10 mg G. CHEWABLE TABLETS OF THE INVENTION
Ingredient Ingredient Composition No.
(% w/w) 1 DCPs 0.10-50.00 2 Sodium ascorbate, USP 12-35 3 Avicel pH 101 5-15 4 Sodium saccharin, N. F. 0.56 (powder) S DiPac 10-30 6 Stearic acid, N. F 2.50 7 Imitation orange flavor 1.00 8 FD&C Yellow#6 dye 0.50 9 Cab-O-Sil 0.50 Procedure: Blend all the ingredients, except 6, for 20 min. in a blender.
Screen in 6 and blend for an additional 5 min. Compress into tablets using 7/16-in standard concave tooling.
H. SYRUP OF THE INVENTION
Ingredient No. Ingredient Quantity per 100 mL
1 DCPs 0.10-50.00% by volume 2 Excipients q.s I. ORAL LIQUID OF THE INVENTION
Ingredient Quantity per 100 ml 1. DCPs 0.10-50.00% by volume 2. Purified Water q. s.
3. Excipients: Preservatives, stabilizers, q. s.
sweetners, flavors, colors, etc.
J. SNACK BAR WITH THE INVENTION
Ingredient Ingredient Quantity per 1 No. K~
1 DCPs 0.50-30.00%
by weight 2 Nutrition Blend: Calcium (Tricalcium Phosphate and q.s Calcium Carbonate), Magnesium (Magnesium Oxide), Vitamin A, Vitamin C, Vitamin D-3, Vitamin B-1 (Thiamin), Vitamin B-2 (Riboflavin), Vitamin B-6 (Pyridoxine), Vitamin B-12 (Cyanocobalamin), Natural Vitamin (Acetate), Niacin, Biotin, Pantothenic Acid, Zinc, Folic Acid, Vitamin K, Selenium. Other Ingredients: Protein Blend (Soy protein isolate, Hydrolyzed collagen, Whey protein isolate, Calcium/Sodium Caseinate ), Glycerine, Polydextrose (fiber), Water, Cocoa Butter, Natural Coconut Oil (non-hydronated), Coconut, Cellulose, Cocoa Powder, Olive Oil, Lecithin, Natural and Artificial Flavor, Maltodextrin, Guar Gum, Citric Acid (Flavor Enhancer), Sucralose K. CEREAL WITH THE INVENTION
Ingredient Ingredient Quantity per 1 Kg No.
1 DCPs 0.50-30.00% by weight 2 Excipients: Whole Grain Oats, Oat Bran, q.s Sugar, Modified Corn Starch, Brown Sugar Syrup, Salt, Calcium Carbonate, Trisodium Phosphate, Wheat Flour, Vitamin E (Mixed tocopherols), Zinc & Iron (Mineral nutrients), Niacinamide (A B Vitamins), Vitamin B6 (Pyridoxine Hcl), Vitamin B2 (Riboflavin), Vitamin B 1 (Thiamin Mononitrate), Vitamin A (Palmitate), Vitamin A B (Folic acid), Vitamin B 12, Vitamin D
L. BEVERAGE WITH THE INVENTION
Ingredient Ingredient Quantity per No. 500 mL
1 DCPs 0.50-30.00%
by volume 2 Excipients: Filtered Water, Food Starch- q.s Modified, Citric Acid, Bitter Orange, Green Tea Extract, Maltodextrin, Whey Protein Isolate, High Fructose Corn Syrup and/or Sucrose and/or Sugar, Sodium Benzoate, Caffeine, Niacin, Glycerol Ester of Wood resin, Flavors, Colors Veterinary Formulations A. CHEWABLE TABLETS OF THE INVENTION
Note: Administer free choice just prior to feeding, or crumble and mix with food Ingredient No. Ingredient Composition 1 DCPs 0.10-50.00 % w/w 2 Calcium (from calcium phosphate) 600 mg 3 Phosphorus (from calcium phosphate) 470 mg 4 Vitamin C 10 mg Vitamin A 750 I. U.
6 Vitamin D3 400 I. U.
7 Excipients q. s.
B. VITAMIN TABLETS OF THE INVENTION (PEANUT BUTTER
FLAVOR
Ingredient Quantity per Tablet 1. DCPs 0.10-50.00% by weight 2. Other Ingredients: q. s.
Brewer's Yeast Powder, Garlic, Whey, Beef Liver, Peanut Butter, Silica Gel, Niacin, Riboflavin, Thiamine Mononitrate, Ascorbic acid C. GRANULES OF THE INVENTION
Ingredient Quantity per 4 oz.
5 1. DCPs 0.10-50.00% by weight 2. Other Ingredients: q.s.
Potassium Gluconate, Wheat, Sucrose, Hydrolyzed Vegetable Protein, Silicone Dioxide, TBHQ (preservative) D. BLOOD BUILDING POWDER OF THE INVENTION
Ingredient Quantity per 1b.
1. DCPs 0.10-50.00% by weight 2. Other Ingredients: q.s.
Heme iron polypeptide, Niacin (Vitamin B3), Vitamin E acetate, Riboflavin (Vitamin B2), Thiamine (Vitamin B1), Pyridoxine (Vitamin B6), Vitamin B12, Copper Sulfate, Cobalt sulfate, Soybean oil, Whey, Natural sweet apple and molasses flavors E. LIQUID CAPSULES OF THE INVENTION
Note: The capsules may be punctured and the liquid contents squeezed onto food, if desired.
S
Ingredient Quantity per Capsule 1. DCPs 0.10-50.00% by weight 2. Other Ingredients: q. s.
Safflower Oil, Gelatin, Fish Oil, Glycerin, Borage Seed Oil, Vitamin E, Water F: ORAL LIQUID OF THE INVENTION
Ingredient Quantity per 100 ml 1. DCPs 0.10-50.00% by volume 2. Purified Water, Sugar, Sorbitol, Polysorbate 80, q.s.
Propylene glycol, Peptones, Ferric ammonium citrate, nicotinamide, Vitamin A and D3 concentrate, d-panthenol, Thiamine Hcl (Vitamin B 1 ), alpha tocopheryl acetate (Vitamin E), saccharine sodium, Vitamin A
palmitate, Pyridoxine Hcl (Vitamin B6), Riboflavin 5'- Phosphate sodium (source of Vitamin B2) 3. Excipients: Preservatives, stabilizers, q.s.
sweeteners, flavors, colors, etc.
G. SUSPENSION OF THE INVENTION
Ingredient Ingredient Quantity per each No. oz.
1 DCPs 0.10-50.00%
2 Fat (Polyunsaturated) 45%
3 Carbohydrate 33%
4 Vitamin A 500 I. U.
Vitamin D3 40 I. U.
6 Vitamin E 3 I. U.
7 Thiamine Hcl (Vitamin B1) 0.15 mg 8 Riboflavin S'Phos Na (Vitamin0.17 mg B2) 9 Pyridoxine Hcl (Vitamin 0.2 mg B6) Ascorbic acid (Vitamin C) 6.0 mg 11 Nicotinamide 2.0 mg 12 Pantothenic acid 1.0 mg 13 Folic acid 0.04 mg 14 Sodium Benzoate 0.1%
5 H. INJECTABLE OF THE INVENTION
Ingredient Quantity per ml 1. DCPs 0.1-10% by volume 10 2. Water for Injection, USP q. s.
3. Ingredients to maintain proper pH q. s.
D. MOISTURE RECOVERY BODY LOTION
Ingredients % w/w Phase A
Demineralized Water 76.45 PVM/MA Decadiene Crosspolymer 0.25 Disodium EDTA 0.15 Hexylene Glycol 2.00 Allantoin 0.10 Phase B
Glyceryl Stearate (and) Behenyl 3.00 Alcohol (and) Palmitic Acid (and) Stearic Acid (and) Lecithin (and) Lauryl Alcohol (and) Myristyl Alcohol (and) Cetyl Alcohol Isopropyl myristate 3.00 Octylhydroxy Stearate 5.00 Isostearyl Neopentanoate 4.00 Phase C
Sodium Hydroxide (10% Aq. Soln.) 0.40 Phase D
Glycerin (and) Glyceryl Polyacrylate2.00 Phenyl Trimethicone 1.00 Cyclopentasiloxane 1.00 DCPs (present invention) 0.50 Phase E
Propylene Glycol (and) Diazolidinyl0.50 Urea (and) Iodopropynyl Butylcarbamate Phenoxyethanol (and) Isopropylparaben0.50 (and) Isobutylparaben (and) Butylparaben Fragrance 0.15 Total 100.00 Procedure:
1. Combine ingredients in Phase A and heat to 80° C for 45 minutes with mixing.
2. Combine ingredients in Phase B. Heat and mix to 75° C - 80° C
3. Add Phase B to Phase A under homogenization. Homogenize until uniform.
4. Add Phase C to Phases A&B. Take off homomix, start cooling.
Switch to propeller mixing to 40° C.
5. Add Phase D ingredients at 40° C, one by one and mix well between each addition.
6. Add Phase E at 35° C. QS for water loss.
E. HAIR SHINE OIL
Ingredients % w/w Phase A
DCPs (present invention) 0.25 Lauryl Lactate 3.00 Phase B
SD Alcohol 40-B (200 proof 16.75 C12-15 Alkyl Benzoate 10.00 Cyclopentasiloxane 59.00 Phenyl Trimethicone 10.00 Phenoxyethanol (and) 1.00 Isopropylparaben (and) Isobutylparaben (and) Butylparaben Total 100.00 Procedure:
1. Add DCPs to Lauryl lactate in a small mixing vessel. Heat the mixture to 60-70° C. Mix well with slow agitation until homogenous. Cool down to 30-35° C
while agitating.
2. Add Alcohol into a separate, larger vessel.
3. When Phase A is at 30-35° C add Phase A to the alcohol. Mix well until homogenous. Add remaining ingredients in order with thorough mixing between each until homogenous.
4. Add the preservative. Mix well until homogenous.
F. SKIN BRIGHTENING / LIGHTENING LOTION FOR FACE
Ingredients % w/w Phase A
x Water (demineralized 65.97 Disodium EDTA 0.10 Propylene Glycol 2.00 Sorbitol 2.00 Sodium Laur 1 Sulfate 0.15 Phase=B - .~.~. =v- _~;.
G1 ceryl stearate 5.00 Stearic acid 1.00 Avocado oil 10.00 Almond oil 5.00 Beeswax 1.50 Phase ,G __ ,m ~--_ _: ~ ,.~_ __ . ~ ._. . -~ -:~~...
.. . ~ .~r=
Water (demineralized) 5.00 DCPs (present invention)1.00 ," _ ~ _:.
_ _ ~ ..
_ ~ ~ ~c Phase D
~_ ~
Triethanolamine 0.28 Phase~E ~. ~ ;
Propylene glycol, DMDM 1.00 H dantoin, Meth 1 araben Total ~ 100.00 Procedure Combine A and heat to 70-75° C. Combine B and heat to 70-75° C. Add B to A while stirring. Add phase C at 30° C. Adjust pH to S.0-6.0 with phase D. Add phase E. Mix until uniform.
Pharmaceutical/ Nutritional Formulations A. TABLETS AND CAPSULES OF THE INVENTION
Ingredient Quantity per Tablet/Capsule 1.DCPs 0.10-50.00% by weight 2.Avicel pH 101 200.00 mg 3.Starch 1500 189.00 mg 4.Stearic acid, N. F. (powder) 8.60 mg S.Cab-O-Sil 2.00 mg Note: The target weight of tablet/capsule is 400 mg; Avicel pH 101 and Starch may be adjusted suitably to reach the target weight. The blended material can be filled into appropriate capsules.
B. ANTI-STRESS SUPPORT TABLETS/CAPSULES OF THE INVENTION
Ingredient Quantity per Tablet/Capsule 1. DCPs 0.10-50.00% by weight 2. Cellulose q. s.
3. Magnesium stearate q. s.
4. Gelatin q. s.
C. CARDIO-VASCULAR SUPPORT TABLETS OF THE INVENTION
Ingredient Quantity per Tablet/Capsule 1. DCPs 10.0 - 50.00% b wei ht 2. Vitamin A (Beta Carotene) 45,000 IU
3. Vitamin B-1 (Thiamin) 25 mg 4. Inositol Hexanicotinate 50 mg 5. Vitamin B-6 (Pyridoxine HCL) 25 mg 6. Vitamin B-12 (Cyanocobalamin) 500 mcg 7. Folic Acid 800 mcg 8. Vitamin C (Magnesium Ascorbate) 150 mg 9. Vitamin E D-alpha Tocophery (Natural)400 IU
10. Copper (Sebacate) 750 mcg 11. Magnesium (Ascorbate, Taurinate, 30 mg and Oxide) 12. Potassium (Citrate) 10 mg 13. Selenium (L-Selenomethionine) 200 mcg 14. Silica (from 400 mg of Horsetail 10 mg Extract) Other Ingredients and Herbs:
15. Coenzyme Q10 (Ubiquinone) 10 mg 16. L-Carnitine L-Tartrate 50 mg 17. Hawathorn Berry Extract 40 mg 19. Grape Seed Extract lOmg 20. L-Proline 50 mg 21. L-Lysine (HCL) 50 mg 22. N-Acetyl Glucosamine 50 mg 23. Bromelain (2,000 GDU per g) 120 mg 24. Taurine (Magnesium Taurinate) 50 mg 25. Inositol (Hexanicotinate) 10 mg D. MULTI-VITAMIN & MINERAL SUPPLEMENT TABLETS OF THE
INVENTION
Quantity per Ingredient Tablet 1. DCPs 0.50-30.00% by weight 2. Vitamin A (beta carotene) 25,000 IIJ
3. Vitamin A (palmitate) 10,000 ILT
4. Vitamin B-1 (Thiamin Nitrate) 10 mg 5. Vitamin B-2 (Riboflavin) 10 mg 6. Inositol Hexanicotinate, Niacinamide20 mg & Niacin 7. Vitamin B-5 (Calcium D-Pantothenate)10 mg 8. Vitamin B-6 ((Phyridoxine HCL) 10 mg 9. Vitamin B-12 (Cyanocobalamin) 200 mcg 10. Biotin 500 mcg 11. Folic Acid 800 mcg 12. Vitamin C 180 mg (Magnesium, Manganese & Zinc Ascorbates) 13. Fat-Soluble Vitamin C 20 mg (from 476 mg of Ascorbyl Palmitate) 14. Vitamin D-3 (Cholecalciferol) 400 ILJ
15. Vitamin E D-alpha Tocopheryl (Natural)600 ILT
16. Boron (Amino Acid Chelate) 2 mg 17. Calcium (Succinate, Carbonate, 20 mg Malate) 18. Copper (Sebacate) 1 mg 19. Iodine (from Kelp) 150 mcg, 150 mcg Magnesium (Ascorbate, Oxide, Succinate) 20. Manganese (Ascorbate) 30 mg 21. Molybdenum (Amino Acid Chelate) 300 mcg 22. Potassium (Succinate, alpha-Ketoglutarate)10 mg 23. Selenium 250 mcg (L-Selenomethionine & Sodium Selenite) 24. Zinc (Zinc Monomethionine & Ascorbate)10 mg Other Ingredients and Plant antioxidants: N-Acetyl Cysteine, Succinic Acid (Free Form), Choline (Bitartrate), Inositol (Hexanicotinate and Inositol), N-Acetyl Glucosamine, DMAE (Bitartrate), N-Acetyl L-Tyrosine, Coenzyme Q 10, Alpha-Lipoic Acid, Quercetin, Milk Thisle Seed Extract, Grape Seed Extract, Ginkgo Biloba, Bilberry Extract.
E. ANTI-DIABETIC SUPPORT TABLETS/CAPSULES OF THE INVENTION
Quantity per Ingredient Tablet/Capsule 5 1. DCPs 0.10-50.00% by weight 2. Vitamin B-6 (as Pyridoxine 10 mg HCI) 3. L-Arginine 50 mg 4. L-Lysine Monohydrochl oride50 mg 5. Cellulose q.s.
10 6. Magnesium stearate q.s.
7. Gelatin q.s.
F. WEIGHT LOSS SUPPORT TABLETS
OF THE INVENTION
Quantity per Ingredient Tablet/Capsule 1. DCPs 0.10-50.00% by weight 2. Garcinia Cambogia Extract 60 mg 3. Bitter Orange Peel Standardized 20 mg Extract 4. Green Tea 10 mg 5. Cayenne 15 mg 6. Mustard Seed 10 mg 7. Ginger Root 10 mg 8. Piper nigrum 10 mg 9. Acetyl L-Carnitine 10 mg 10. Niacinamide 10 mg 11. Vitamin B-6 (Pyridoxine HCL) 10 mg G. CHEWABLE TABLETS OF THE INVENTION
Ingredient Ingredient Composition No.
(% w/w) 1 DCPs 0.10-50.00 2 Sodium ascorbate, USP 12-35 3 Avicel pH 101 5-15 4 Sodium saccharin, N. F. 0.56 (powder) S DiPac 10-30 6 Stearic acid, N. F 2.50 7 Imitation orange flavor 1.00 8 FD&C Yellow#6 dye 0.50 9 Cab-O-Sil 0.50 Procedure: Blend all the ingredients, except 6, for 20 min. in a blender.
Screen in 6 and blend for an additional 5 min. Compress into tablets using 7/16-in standard concave tooling.
H. SYRUP OF THE INVENTION
Ingredient No. Ingredient Quantity per 100 mL
1 DCPs 0.10-50.00% by volume 2 Excipients q.s I. ORAL LIQUID OF THE INVENTION
Ingredient Quantity per 100 ml 1. DCPs 0.10-50.00% by volume 2. Purified Water q. s.
3. Excipients: Preservatives, stabilizers, q. s.
sweetners, flavors, colors, etc.
J. SNACK BAR WITH THE INVENTION
Ingredient Ingredient Quantity per 1 No. K~
1 DCPs 0.50-30.00%
by weight 2 Nutrition Blend: Calcium (Tricalcium Phosphate and q.s Calcium Carbonate), Magnesium (Magnesium Oxide), Vitamin A, Vitamin C, Vitamin D-3, Vitamin B-1 (Thiamin), Vitamin B-2 (Riboflavin), Vitamin B-6 (Pyridoxine), Vitamin B-12 (Cyanocobalamin), Natural Vitamin (Acetate), Niacin, Biotin, Pantothenic Acid, Zinc, Folic Acid, Vitamin K, Selenium. Other Ingredients: Protein Blend (Soy protein isolate, Hydrolyzed collagen, Whey protein isolate, Calcium/Sodium Caseinate ), Glycerine, Polydextrose (fiber), Water, Cocoa Butter, Natural Coconut Oil (non-hydronated), Coconut, Cellulose, Cocoa Powder, Olive Oil, Lecithin, Natural and Artificial Flavor, Maltodextrin, Guar Gum, Citric Acid (Flavor Enhancer), Sucralose K. CEREAL WITH THE INVENTION
Ingredient Ingredient Quantity per 1 Kg No.
1 DCPs 0.50-30.00% by weight 2 Excipients: Whole Grain Oats, Oat Bran, q.s Sugar, Modified Corn Starch, Brown Sugar Syrup, Salt, Calcium Carbonate, Trisodium Phosphate, Wheat Flour, Vitamin E (Mixed tocopherols), Zinc & Iron (Mineral nutrients), Niacinamide (A B Vitamins), Vitamin B6 (Pyridoxine Hcl), Vitamin B2 (Riboflavin), Vitamin B 1 (Thiamin Mononitrate), Vitamin A (Palmitate), Vitamin A B (Folic acid), Vitamin B 12, Vitamin D
L. BEVERAGE WITH THE INVENTION
Ingredient Ingredient Quantity per No. 500 mL
1 DCPs 0.50-30.00%
by volume 2 Excipients: Filtered Water, Food Starch- q.s Modified, Citric Acid, Bitter Orange, Green Tea Extract, Maltodextrin, Whey Protein Isolate, High Fructose Corn Syrup and/or Sucrose and/or Sugar, Sodium Benzoate, Caffeine, Niacin, Glycerol Ester of Wood resin, Flavors, Colors Veterinary Formulations A. CHEWABLE TABLETS OF THE INVENTION
Note: Administer free choice just prior to feeding, or crumble and mix with food Ingredient No. Ingredient Composition 1 DCPs 0.10-50.00 % w/w 2 Calcium (from calcium phosphate) 600 mg 3 Phosphorus (from calcium phosphate) 470 mg 4 Vitamin C 10 mg Vitamin A 750 I. U.
6 Vitamin D3 400 I. U.
7 Excipients q. s.
B. VITAMIN TABLETS OF THE INVENTION (PEANUT BUTTER
FLAVOR
Ingredient Quantity per Tablet 1. DCPs 0.10-50.00% by weight 2. Other Ingredients: q. s.
Brewer's Yeast Powder, Garlic, Whey, Beef Liver, Peanut Butter, Silica Gel, Niacin, Riboflavin, Thiamine Mononitrate, Ascorbic acid C. GRANULES OF THE INVENTION
Ingredient Quantity per 4 oz.
5 1. DCPs 0.10-50.00% by weight 2. Other Ingredients: q.s.
Potassium Gluconate, Wheat, Sucrose, Hydrolyzed Vegetable Protein, Silicone Dioxide, TBHQ (preservative) D. BLOOD BUILDING POWDER OF THE INVENTION
Ingredient Quantity per 1b.
1. DCPs 0.10-50.00% by weight 2. Other Ingredients: q.s.
Heme iron polypeptide, Niacin (Vitamin B3), Vitamin E acetate, Riboflavin (Vitamin B2), Thiamine (Vitamin B1), Pyridoxine (Vitamin B6), Vitamin B12, Copper Sulfate, Cobalt sulfate, Soybean oil, Whey, Natural sweet apple and molasses flavors E. LIQUID CAPSULES OF THE INVENTION
Note: The capsules may be punctured and the liquid contents squeezed onto food, if desired.
S
Ingredient Quantity per Capsule 1. DCPs 0.10-50.00% by weight 2. Other Ingredients: q. s.
Safflower Oil, Gelatin, Fish Oil, Glycerin, Borage Seed Oil, Vitamin E, Water F: ORAL LIQUID OF THE INVENTION
Ingredient Quantity per 100 ml 1. DCPs 0.10-50.00% by volume 2. Purified Water, Sugar, Sorbitol, Polysorbate 80, q.s.
Propylene glycol, Peptones, Ferric ammonium citrate, nicotinamide, Vitamin A and D3 concentrate, d-panthenol, Thiamine Hcl (Vitamin B 1 ), alpha tocopheryl acetate (Vitamin E), saccharine sodium, Vitamin A
palmitate, Pyridoxine Hcl (Vitamin B6), Riboflavin 5'- Phosphate sodium (source of Vitamin B2) 3. Excipients: Preservatives, stabilizers, q.s.
sweeteners, flavors, colors, etc.
G. SUSPENSION OF THE INVENTION
Ingredient Ingredient Quantity per each No. oz.
1 DCPs 0.10-50.00%
2 Fat (Polyunsaturated) 45%
3 Carbohydrate 33%
4 Vitamin A 500 I. U.
Vitamin D3 40 I. U.
6 Vitamin E 3 I. U.
7 Thiamine Hcl (Vitamin B1) 0.15 mg 8 Riboflavin S'Phos Na (Vitamin0.17 mg B2) 9 Pyridoxine Hcl (Vitamin 0.2 mg B6) Ascorbic acid (Vitamin C) 6.0 mg 11 Nicotinamide 2.0 mg 12 Pantothenic acid 1.0 mg 13 Folic acid 0.04 mg 14 Sodium Benzoate 0.1%
5 H. INJECTABLE OF THE INVENTION
Ingredient Quantity per ml 1. DCPs 0.1-10% by volume 10 2. Water for Injection, USP q. s.
3. Ingredients to maintain proper pH q. s.
Claims (38)
1. A composition of dibenzo-alpha-pyrones chromoproteins (DCPs) comprising:
a. dibenzo-alpha-pyrones or their derivatives;
b. phosphocreatine;
c. chromo-peptides of molecular weights of about <= 2 KD; and d. lipids having fatty acyl esters of glycerol.
a. dibenzo-alpha-pyrones or their derivatives;
b. phosphocreatine;
c. chromo-peptides of molecular weights of about <= 2 KD; and d. lipids having fatty acyl esters of glycerol.
2. A composition according to claim 1 comprising said dibenzo-alpha-pyrones of formula (I) wherein:
R1 is selected from the group consisting of H, OH, O-acyl, and O-amino-acyl;
and R5, R6, R7, R8, R9, and R10 are independently selected from the group consisting of H, OH, O-acyl, O-amino-acyl, and fatty acyl groups.
R1 is selected from the group consisting of H, OH, O-acyl, and O-amino-acyl;
and R5, R6, R7, R8, R9, and R10 are independently selected from the group consisting of H, OH, O-acyl, O-amino-acyl, and fatty acyl groups.
3. A composition according to claim 1 wherein said phosphocreatine is attached to the 3- or 8-position of said dibenzo-alpha-pyrones via an ester linkage.
4. A composition according to claim 1 wherein said chromo-peptides further comprise:
one or more amino acids;
carotenoids; and indigoids.
one or more amino acids;
carotenoids; and indigoids.
5. A composition according to claim 1 wherein said chromo-proteins have a molecular weight of about 2 to about 20 KD.
6. A composition according to claim 5 wherein said chromo-proteins comprise of one or more amino acids selected from the group consisting of methionine, arginine, glycine, alanine, threonine, serine, proline, and hydroxyproline.
7. A composition according to claim 1 wherein said chromo-peptides comprise of a carotenoid moiety, said carotenoid moiety is astaxanthin and equivalents.
8. A composition according to claim 1 wherein said lipids are saturated or unsaturated fatty acids having a carbon chain length of about C14 to C24.
9. A composition according to claim 8 wherein said polyunsaturated fatty acid substituents have a degree of unsaturation of one to six.
10. A composition according to claim 9 wherein said polyunsaturated fatty acids are eicosapentaenoic acid and / or docosahexaenoic acid.
11. A composition according to claim 1 wherein said DCPs further comprise iron, calcium, copper, zinc, magnesium, vanadium, and/or metal ions ranging from about 1 to about 500 ppm levels.
12. A composition according to claim 1 wherein said DCPs further comprise low molecular weight ligands.
13. A skin care, hair care, pharmaceutical, or nutritional or veterinary formulation comprising the composition of claim 1 present therein in an amount of about 0.05 to about 50% by weight.
14. A skin care or protection formulation according to claim 13 where said skin care or protection formula is in the form of a lotion, cream, gel or spray, and said composition is present in an amount of about 0.05 to about 5% by weight.
15. A pharmaceutical formulation according to claim 13 wherein said pharmaceutical formulation is in the form of a tablet, syrup, elixir or capsule.
16. A nutritional formulation according to claim 13 wherein said nutritional formulation contains about 0.5 to about 30% of said composition.
17. A skin care or protection formulation according to claim 14, further comprising a cosmetically acceptable carrier and at least one cosmetic adjuvant selected from the group consisting of sunscreens, antioxidants, preservatives, self tanning agent, perfumes, oils, waxes, propellants, waterproofing agents, emulsifiers, thickeners, humectants, and emollients.
18. A pharmaceutical formulation according to claim 15 further comprising pharmaceutically acceptable carriers.
19. A nutritional formulation according to claim 16 further comprising nutritionally acceptable carriers.
20. A process for isolating DCP compositions according to claim 1 from shilajit compositions comprising at least 0.5%-10% w/w dibenzo-alpha-pyronechromoproteins, said process comprising the steps of:
1) powdering native shilajit rock material and extracting it successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration;
2) triturating said ethyl acetate and methanol insoluble material with hot water and then citrate buffer of pH 5.0;
3) filtering the combined extract-mixture to remove insoluble substances comprising polymeric humic materials, minerals and metal ion salts;
4) gradually saturating the combined aqueous filtrate with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating said combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering said DCPs and evaporating the filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from shilajit.
1) powdering native shilajit rock material and extracting it successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration;
2) triturating said ethyl acetate and methanol insoluble material with hot water and then citrate buffer of pH 5.0;
3) filtering the combined extract-mixture to remove insoluble substances comprising polymeric humic materials, minerals and metal ion salts;
4) gradually saturating the combined aqueous filtrate with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating said combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering said DCPs and evaporating the filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from shilajit.
21. A process according to claim 20 wherein said shilajit composition is about 12% to about 40% w/w dibenzo-alpha-pyronechromoproteins.
22. A process for isolating DCP compositions according to claim 1 from fossils of ammonites, said process comprising the steps of:
1) powdering ammonite fossil materials and extracting it successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration;
2) triturating said ethyl acetate and methanol insoluble material with 0.1 N HCI;
3) filtering the aqueous acidic extract to remove insoluble substances comprising polymeric humic materials and dissolving in minimum volume of water;
4) gradually saturating the aqueous solution with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating said combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering said DCPs and evaporating filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from fossils of ammonites.
1) powdering ammonite fossil materials and extracting it successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration;
2) triturating said ethyl acetate and methanol insoluble material with 0.1 N HCI;
3) filtering the aqueous acidic extract to remove insoluble substances comprising polymeric humic materials and dissolving in minimum volume of water;
4) gradually saturating the aqueous solution with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating said combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering said DCPs and evaporating filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from fossils of ammonites.
23. A process for isolating DCP compositions according to claim 1 from fossils of corals, said process comprising the steps of:
1) powdering coral fossil materials and extracting it successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration;
2) triturating said ethyl acetate and methanol insoluble material with 0.1 N HCl;
3) filtering the aqueous acidic extract to remove insoluble substances comprising polymeric humic materials and dissolving in minimum volume of water, 4) gradually saturating the aqueous solution with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating said combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering said DCPs and evaporating filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from fossils of corals.
1) powdering coral fossil materials and extracting it successively with hot ethyl acetate and methanol to remove the soluble low and medium molecular weight organic compounds by filtration;
2) triturating said ethyl acetate and methanol insoluble material with 0.1 N HCl;
3) filtering the aqueous acidic extract to remove insoluble substances comprising polymeric humic materials and dissolving in minimum volume of water, 4) gradually saturating the aqueous solution with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating said combined aqueous solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering said DCPs and evaporating filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from fossils of corals.
24. A process for isolating DCP compositions according to claim 1 from invertebrates, said process comprising the steps of:
1) extracting body flesh with hot ethyl acetate to remove low molecular weight free organic compounds and lipids as the soluble fraction;
2) extracting said ethyl acetate with Bligh and Dyer solvent system;
3) evaporating said Bligh and Dyer solvent extractive under reduced pressure and dissolving in minimum volume of water;
4) gradually saturating said water with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating said combined water solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering said DCPs and evaporating filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from invertebrates.
1) extracting body flesh with hot ethyl acetate to remove low molecular weight free organic compounds and lipids as the soluble fraction;
2) extracting said ethyl acetate with Bligh and Dyer solvent system;
3) evaporating said Bligh and Dyer solvent extractive under reduced pressure and dissolving in minimum volume of water;
4) gradually saturating said water with increasing concentrations of ammonium sulphate to obtain purple-brown precipitate of mixture of DCPs, or concentrating said combined water solution and adding acetone to precipitate DCPs as brownish-red or off white precipitate and filtering said DCPs and evaporating filtrate to obtain an additional lot of mixture of DCPs of lesser complexities; and 5) fractionating the purple-brown solid residues, obtained from ammonium sulphate saturation by Sephadex gel-filtration and electrophoresis to isolate DCP compositions from invertebrates.
25. A method for treating chronic stress, comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 1.
26. A composition comprising of dibenzo-alpha-pyrone chromoproteins (DCPs) of formula (I):
wherein:
R1 is selected from the group consisting of H, OH, O-acyl, and O-amino-acyl;
R2 is selected from H and CH3;
R3 is selected from H and fatty acids;
R4 is selected from H and fatty acids; and R5, R6, R7, R8, R9, and R10 are independently selected from the group consisting of H, OH, O-acyl, O-amino-acyl, and fatty acyl groups.
wherein:
R1 is selected from the group consisting of H, OH, O-acyl, and O-amino-acyl;
R2 is selected from H and CH3;
R3 is selected from H and fatty acids;
R4 is selected from H and fatty acids; and R5, R6, R7, R8, R9, and R10 are independently selected from the group consisting of H, OH, O-acyl, O-amino-acyl, and fatty acyl groups.
27. A composition according to claim 26 wherein said DCPs further comprise iron, calcium, copper, zinc, magnesium, vanadium, and/or metal ions ranging from about 1 to 500 ppm levels.
28. A composition of claim 27 wherein said DCPs further comprise low molecular weight ligands.
29. A skin care, hair care, pharmaceutical, or nutritional formulation comprising the composition of claim 26 present therein in an amount of about 0.05 to 50% by weight.
30. A method for treating chronic stress disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 26.
31. A method for increasing a cognition effect of learning, comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 13.
32. A method for treating stress disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 13.
33. A method according to claim 32, wherein the disorder is selected from anxiety induced stress, depression induced stress, thermic change induced stress, gastric ulcer induced stress, convulsion induced stress, and adrenocortial induced stress.
34. A method for modulation of an immune system by increasing antioxidant defense enzymes selected from the group consisting of super oxide dismutase (SOD), catalase, and glutathione peroxidase comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 13.
35. A method for increasing a cognition effect of learning, comprising administering ,to a patient in need thereof a therapeutically effective amount of a composition according to claim 29.
36. A method for treating stress disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 29.
37. A method according to claim 36, wherein the disorder is selected from anxiety induced stress, depression induced stress, thermic change induced stress, gastric ulcer induced stress, convulsion induced stress, and adrenocortial induced stress.
38. A method for modulation of an immune system by increasing antioxidant defense enzymes selected from the group consisting of super oxide dismutase (SOD), catalase, and glutathione peroxidase comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 29.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/824,271 US20050233942A1 (en) | 2004-04-14 | 2004-04-14 | Oxygenated dibenzo-alpha-pyrone chromoproteins |
US10/824,271 | 2004-04-14 | ||
US10/799,104 US20050245434A1 (en) | 2004-04-30 | 2004-04-30 | Oxygenated dibenzo-alpha-pyrone chromoproteins |
US10/799,104 | 2004-04-30 | ||
PCT/US2005/008577 WO2005099739A1 (en) | 2004-04-14 | 2005-03-14 | Oxygenated dibenzo-alpha-pyrone chromoproteins |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2562829A1 true CA2562829A1 (en) | 2005-10-27 |
Family
ID=35149775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002562829A Abandoned CA2562829A1 (en) | 2004-04-14 | 2005-03-14 | Oxygenated dibenzo-alpha-pyrone chromoproteins |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1750739A4 (en) |
JP (1) | JP2008504231A (en) |
CA (1) | CA2562829A1 (en) |
WO (1) | WO2005099739A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050282781A1 (en) * | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
CZ303199B6 (en) * | 2010-08-02 | 2012-05-23 | T-String Pardubice, A. S. | Process for preparing mummy liposome |
JP2017014154A (en) * | 2015-07-01 | 2017-01-19 | 公立大学法人岡山県立大学 | Hyaluronic acid production promoter containing urolithins |
JP6799767B2 (en) * | 2015-07-07 | 2020-12-16 | 公立大学法人岡山県立大学 | Melanin production inhibitor containing urolithins |
CN106666538A (en) * | 2017-01-05 | 2017-05-17 | 徐文轩 | Preparation method of dried day lilies |
JP7152344B2 (en) * | 2019-03-27 | 2022-10-12 | 富士フイルム株式会社 | Oil-in-water cosmetics |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405613A (en) * | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
US6440436B1 (en) * | 2001-05-18 | 2002-08-27 | Natreon Inc. | Process for preparing purified shilajit composition from native shilajit |
US7250181B2 (en) * | 2005-01-19 | 2007-07-31 | Natreon, Inc. | Polyherbal compositions and methods for treating viral infections |
-
2005
- 2005-03-14 JP JP2007508354A patent/JP2008504231A/en active Pending
- 2005-03-14 CA CA002562829A patent/CA2562829A1/en not_active Abandoned
- 2005-03-14 WO PCT/US2005/008577 patent/WO2005099739A1/en active Application Filing
- 2005-03-14 EP EP05779897A patent/EP1750739A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2005099739A1 (en) | 2005-10-27 |
JP2008504231A (en) | 2008-02-14 |
EP1750739A4 (en) | 2010-05-05 |
EP1750739A1 (en) | 2007-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pawar et al. | Phytosome as a novel biomedicine: a microencapsulated drug delivery system | |
US5804168A (en) | Pharmaceutical compositions and methods for protecting and treating sun damaged skin | |
Acid | Final report on the safety assessment of oleic acid, laurie acid, palmitic acid, myristic acid, and stearic acid | |
US4895839A (en) | Pharmaceutical and cosmetic compositions containing complexes of flavanolignans with phospholipids | |
EP1002526B1 (en) | Skin whitening composition containing bearberry extract and a reducing agent | |
US5104655A (en) | Polyunsaturated acids having vasokinetic action and pharmaceutical and cosmetic formulations containing them | |
KR100315502B1 (en) | Skin whitening agent containing acerola cherry fermentation material | |
JP3610983B2 (en) | Ascorbyl-phosphoryl-cholesterol | |
KR101364470B1 (en) | Pharmaceutical composition for treating acne | |
EP1667699B1 (en) | Compositions comprising lotus extracts and methyl donors | |
MXPA06009979A (en) | Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenetic alopecia. | |
KR20080026663A (en) | A composition for oral use | |
JPH0676335B2 (en) | Complex of Vitis vinifera extract and phospholipid, method for producing the same, pharmaceutical and cosmetics | |
WO2000048551A1 (en) | Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof | |
JPH07300421A (en) | Anti-inflammatory agent | |
UA89510C2 (en) | Composition based on vegetal extracts of ajuga reptans for preventing hair loss, stimulating the growth of hair, regulating the production of sebum | |
WO2006134248A1 (en) | Use of a griffonia extract, in particular griffonia simplicifolia, in a cosmetic or dermatological composition for mitigating pigmentation of skin and skin appendages | |
CA2562829A1 (en) | Oxygenated dibenzo-alpha-pyrone chromoproteins | |
DE60317639T2 (en) | COMPOSITIONS CONTAIN N-ACYL-PHOSPHATIDYL-ETHANOLAMINE AND / OR MIXTURES OF N-ACYL-ETHANOLAMINES WITH PHOSPHATIDINIC ACIDS OR LYSOPHOSPHATIDINIC ACIDS | |
DE69305433T2 (en) | Cosmetic or dermatological composition for skin depigmentation containing a di- or tri-caffeoylquinic acid or a mixture thereof | |
US20050245434A1 (en) | Oxygenated dibenzo-alpha-pyrone chromoproteins | |
US20050233942A1 (en) | Oxygenated dibenzo-alpha-pyrone chromoproteins | |
KR102577747B1 (en) | Cosmetic composition comprising champsocephalus gunnari extract or notothenia rossii extract as an active ingredient for improving wrinkles | |
KR100566857B1 (en) | Cosmetic Composition of Lifting and Whitening Ingredient Containing Saponin extracted from Rhynchosia Molubilis | |
AU2002237310B2 (en) | Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |